Study on the construction of nomogram prediction model for prognostic assessment of heart failure patients based on serological markers and echocardiography

OBJECTIVE

We aimed to construct a nomogram prediction model for prognostic assessment of patients with heart failure (HF) based on serological markers and echocardiography.

PATIENTS AND METHODS

A total of 200 HF patients admitted to the Second Affiliated Hospital of Nanchang University from January 2018 to January 2020 were selected as the research objects. According to the New York Heart Association (NYHA) cardiac function classification, they were divided into 3 groups, including 65 cases of grade II, 97 cases of grade III, and 38 cases of grade IV. Three groups of echocardiographic parameters were compared [including left ventricular ejection fraction (LVEF), left ventricular end-diastolic diameter (LVEDD), left ventricular end-systolic diameter (LVESD), left ventricular end-systolic volume (LVESV)], differences in serum markers brain natriuretic peptide (BNP), soluble growth-stimulating expression gene 2 (sST2) and the Modified Early Warning Score (MEWS). The patients were divided into two groups according to their clinical outcomes during the follow-up period, including 52 cases in the death group and 148 cases in the survival group. The clinical data of the two groups were compared, and multi-factor logistic regression analysis was performed to screen out the independent risk factors affecting the patient's death. A nomogram model of the patient's mortality risk was constructed based on the independent risk factors. Receiver operating characteristic (ROC) curves and calibration curves were used to evaluate the discrimination and accuracy of the nomogram model.

RESULTS

As the cardiac function class of elderly chronic heart failure (CHF) patients increases, LVEDD, LVESD, sST2, and MEWS increase and LVEF decreases (p<0.05). Multifactor analysis results showed that LVEF, LVEDD, sST2, and MEWS were independent factors affecting the clinical outcome of patients. The AUCs predicted using LVEF, LVEDD, sST2, and MEWS alone were 0.738, 0.775, 0.717, 0.831, and 0.768, respectively. There is a certain degree of discrimination, and the model has extremely high accuracy.

CONCLUSIONS

MEWS, LVEDD, and sST2 increase as the NYHA cardiac function grade of HF patients increases and LVEF decreases, which can reflect the severity of the disease to a certain extent. Additionally, the nomogram model established based on this has a high predictive value for the long-term prognosis of patients and can formulate effective intervention measures for quantitative values.

HMGN1 down-regulation in the diabetic kidney attenuates tubular cells injury and protects against renal inflammation via suppressing MCP-1 and KIM-1 expression through TLR4

BACKGROUND

Renal tubular injury, accompanied by damaging inflammation, has been identified to drive diabetic kidney disease (DKD) toward end-stage renal disease. However, it is unclear how damage-associated molecular patterns (DAMPs) activate innate immunity to mediate tubular epithelial cell (TEC) injury, which in turn causes with subsequent sterile inflammation in diabetic kidneys. High mobility group nucleosome-binding protein 1 (HMGN1) is a novel DAMP that contributes to generating the innate immune response. In this study, we focused on determining whether HMGN1 is involved in DKD progression.

METHODS

Streptozotocin (STZ)-induced diabetic mice model was established. Then we downrergulated HMGN1 expression in kidney with or without HMGN1 administration. The renal dysfunction and morphological lesions in the kidneys were evaluated. The expressions of KIM-1, MCP-1, F4/80, CD68, and HMGN1/TLR4 signaling were examined in the renal tissue. In vitro, HK2 cells were exposed in the high glucose with or without HMGN1, and further pre-incubated with TAK242 was applied to elucidate the underlying mechanism.

RESULTS

We demonstrated that HMGN1 was upregulated in the tubular epithelial cells of streptozotocin (STZ)-induced type 1 and type 2 diabetic mouse kidneys compared to controls, while being positively correlated with increased TLR4, KIM-1, and MCP-1. Down-regulation of renal HMGN1 attenuated diabetic kidney injury, decreased the TLR4, KIM-1, and MCP-1 expression levels, and reduced interstitial infiltrating macrophages. However, these phenotypes were reversed after administration of HMGN1. In HK-2 cells, HMGN1 promoted the expression of KIM-1 and MCP-1 via regulating MyD88/NF-κB pathway; inhibition of TLR4 effectively diminished the in vitro response to HMGN1.

CONCLUSIONS

Our study provides novel insight into HMGN1 signaling mechanisms that contribute to tubular sterile injury and low-grade inflammation in DKD. The study findings may help to develop new HMGN1-targeted approaches as therapy for immune-mediated kidney damage rather than as an anti-infection treatments.

Amplitude Analysis of the B^{0}→K^{*0}μ^{+}μ^{-} Decay

An amplitude analysis of the B^{0}→K^{*0}μ^{+}μ^{-} decay is presented using a dataset corresponding to an integrated luminosity of 4.7  fb^{-1} of pp collision data collected with the LHCb experiment. For the first time, the coefficients associated to short-distance physics effects, sensitive to processes beyond the standard model, are extracted directly from the data through a q^{2}-unbinned amplitude analysis, where q^{2} is the μ^{+}μ^{-} invariant mass squared. Long-distance contributions, which originate from nonfactorizable QCD processes, are systematically investigated, and the most accurate assessment to date of their impact on the physical observables is obtained. The pattern of measured corrections to the short-distance couplings is found to be consistent with previous analyses of b- to s-quark transitions, with the largest discrepancy from the standard model predictions found to be at the level of 1.8 standard deviations. The global significance of the observed differences in the decay is 1.4 standard deviations.

[Incidence of postoperative complications in Chinese patients with gastric or colorectal cancer based on a national, multicenter, prospective, cohort study]

Objective: To investigate the incidence of postoperative complications in Chinese patients with gastric or colorectal cancer, and to evaluate the risk factors for postoperative complications. Methods: This was a national, multicenter, prospective, registry-based, cohort study of data obtained from the database of the Prevalence of Abdominal Complications After Gastro- enterological Surgery (PACAGE) study sponsored by the China Gastrointestinal Cancer Surgical Union. The PACAGE database prospectively collected general demographic characteristics, protocols for perioperative treatment, and variables associated with postoperative complications in patients treated for gastric or colorectal cancer in 20 medical centers from December 2018 to December 2020. The patients were grouped according to the presence or absence of postoperative complications. Postoperative complications were categorized and graded in accordance with the expert consensus on postoperative complications in gastrointestinal oncology surgery and Clavien-Dindo grading criteria. The incidence of postoperative complications of different grades are presented as bar charts. Independent risk factors for occurrence of postoperative complications were identified by multifactorial unconditional logistic regression. Results: The study cohort comprised 3926 patients with gastric or colorectal cancer, 657 (16.7%) of whom had a total of 876 postoperative complications. Serious complications (Grade III and above) occurred in 4.0% of patients (156/3926). The rate of Grade V complications was 0.2% (7/3926). The cohort included 2271 patients with gastric cancer with a postoperative complication rate of 18.1% (412/2271) and serious complication rate of 4.7% (106/2271); and 1655 with colorectal cancer, with a postoperative complication rate of 14.8% (245/1655) and serious complication rate of 3.0% (50/1655). The incidences of anastomotic leakage in patients with gastric and colorectal cancer were 3.3% (74/2271) and 3.4% (56/1655), respectively. Abdominal infection was the most frequently occurring complication, accounting for 28.7% (164/572) and 39.5% (120/304) of postoperative complications in patients with gastric and colorectal cancer, respectively. The most frequently occurring grade of postoperative complication was Grade II, accounting for 65.4% (374/572) and 56.6% (172/304) of complications in patients with gastric and colorectal cancers, respectively. Multifactorial analysis identified (1) the following independent risk factors for postoperative complications in patients in the gastric cancer group: preoperative comorbidities (OR=2.54, 95%CI: 1.51-4.28, P<0.001), neoadjuvant therapy (OR=1.42, 95%CI:1.06-1.89, P=0.020), high American Society of Anesthesiologists (ASA) scores (ASA score 2 points:OR=1.60, 95% CI: 1.23-2.07, P<0.001, ASA score ≥3 points:OR=0.43, 95% CI: 0.25-0.73, P=0.002), operative time >180 minutes (OR=1.81, 95% CI: 1.42-2.31, P<0.001), intraoperative bleeding >50 mL (OR=1.29,95%CI: 1.01-1.63, P=0.038), and distal gastrectomy compared with total gastrectomy (OR=0.65,95%CI: 0.51-0.83, P<0.001); and (2) the following independent risk factors for postoperative complications in patients in the colorectal cancer group: female (OR=0.60, 95%CI: 0.44-0.80, P<0.001), preoperative comorbidities (OR=2.73, 95%CI: 1.25-5.99, P=0.030), neoadjuvant therapy (OR=1.83, 95%CI:1.23-2.72, P=0.008), laparoscopic surgery (OR=0.47, 95%CI: 0.30-0.72, P=0.022), and abdominoperineal resection compared with low anterior resection (OR=2.74, 95%CI: 1.71-4.41, P<0.001). Conclusion: Postoperative complications associated with various types of infection were the most frequent complications in patients with gastric or colorectal cancer. Although the risk factors for postoperative complications differed between patients with gastric cancer and those with colorectal cancer, the presence of preoperative comorbidities, administration of neoadjuvant therapy, and extent of surgical resection, were the commonest factors associated with postoperative complications in patients of both categories.

[Spatial distribution pattern of local tumor progression analysis after microwave ablation of hepatocellular carcinoma based on three-dimensional magnetic resonance imaging]

Objective: To investigate the spatial distribution pattern of local tumor progression (LTP) for hepatocellular carcinoma (HCC) ≤5 cm after microwave ablation. Methods: A retrospective analysis was performed on 169 HCCs with matched MRI before and after ablation from December 2009 to December 2019. A tumor MRI was reconstructed using three-dimensional visualization technology. LTP was classified as contact or non-contact, early or late stage, according to whether LTP was in contact with the edge of the ablation zone and the occurrence time (24 months). The tumor-surrounded area was divided into eight quadrants by using the eight-quadrant map method. An analysis was conducted on the spatial correlation between the quadrant where the ablative margin (AM) safety boundary was located and the quadrant where different types of LTP occurred. The t-test, or rank-sum test, was used for the measurement data. 2-test for count data was used to compare the difference between the two groups. Results: The AM quadrant had a distribution of 54.4% LTP, 64.2% early LTP stage, and 69.1% contact LTP, suggesting this quadrant was much more concentrated than the other quadrants (P < 0.001). Additionally, the AM quadrant had only 15.2% of non-contact type LTP and 17.1% of late LTP, which was not significantly different from the average distribution probability of 12.5% (100/8%) among the eight quadrants (P = 0.667, 0.743). 46.6% of early contact type LTP was located at the ablation needle tip, 25.2% at the body, and 28.1% at the caudal, while the location distribution probabilities of non-early contact LTP were 34.8%, 31.8%, and 33.3%, respectively. Conclusion: LTP mostly occurs in areas where the ablation safety boundary is the shortest. However, non-contact LTP and late LTP stages exhibit the feature of uniform distribution. Thus, this type of LPT may result from an inadequate non-ablation safety boundary.

Fraction of χ_{c} Decays in Prompt J/ψ Production Measured in pPb Collisions at sqrt[s_{NN}]=8.16 TeV

The fraction of χ_{c1} and χ_{c2} decays in the prompt J/ψ yield, F_{χ_{c}→J/ψ}=σ_{χ_{c}→J/ψ}/σ_{J/ψ}, is measured by the LHCb detector in pPb collisions at sqrt[s_{NN}]=8.16  TeV. The study covers the forward (1.5 Collapse

Key Words Collapse

MESH Headings Collapse

Grants Collapse

Affiliation(s)

R Aaij Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
A S W Abdelmotteleb Department of Physics, University of Warwick, Coventry, United Kingdom
C Abellan Beteta Physik-Institut, Universität Zürich, Zürich, Switzerland
F Abudinén Department of Physics, University of Warwick, Coventry, United Kingdom
T Ackernley Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
B Adeva Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
M Adinolfi H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
P Adlarson Department of Physics and Astronomy, Uppsala University, Uppsala, Sweden (associated with School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom)
C Agapopoulou European Organization for Nuclear Research (CERN), Geneva, Switzerland
C A Aidala University of Michigan, Ann Arbor, Michigan, USA (associated with Syracuse University, Syracuse, New York, USA)
Z Ajaltouni Université Clermont Auvergne, CNRS/IN2P3, LPC, Clermont-Ferrand, France
S Akar University of Cincinnati, Cincinnati, Ohio, USA
K Akiba Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
P Albicocco INFN Laboratori Nazionali di Frascati, Frascati, Italy
J Albrecht Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
F Alessio European Organization for Nuclear Research (CERN), Geneva, Switzerland
M Alexander School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
A Alfonso Albero ICCUB, Universitat de Barcelona, Barcelona, Spain
Z Aliouche Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
P Alvarez Cartelle Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
R Amalric LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France
S Amato Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
J L Amey H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
Y Amhis Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France European Organization for Nuclear Research (CERN), Geneva, Switzerland
L An School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
L Anderlini INFN Sezione di Firenze, Firenze, Italy
M Andersson Physik-Institut, Universität Zürich, Zürich, Switzerland
A Andreianov Affiliated with an institute covered by a cooperation agreement with CERN
P Andreola Physik-Institut, Universität Zürich, Zürich, Switzerland
M Andreotti INFN Sezione di Ferrara, Ferrara, Italy
D Andreou Syracuse University, Syracuse, New York, USA
A A Anelli INFN Sezione di Milano-Bicocca, Milano, Italy
D Ao University of Chinese Academy of Sciences, Beijing, China
F Archilli INFN Sezione di Roma Tor Vergata, Roma, Italy
M Argenton INFN Sezione di Ferrara, Ferrara, Italy
S Arguedas Cuendis Consejo Nacional de Rectores (CONARE), San Jose, Costa Rica
A Artamonov Affiliated with an institute covered by a cooperation agreement with CERN
M Artuso Syracuse University, Syracuse, New York, USA
E Aslanides Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
M Atzeni Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
B Audurier Laboratoire Leprince-Ringuet, CNRS/IN2P3, Ecole Polytechnique, Institut Polytechnique de Paris, Palaiseau, France
D Bacher Department of Physics, University of Oxford, Oxford, United Kingdom
I Bachiller Perea Université Savoie Mont Blanc, CNRS, IN2P3-LAPP, Annecy, France
S Bachmann Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
M Bachmayer Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
J J Back Department of Physics, University of Warwick, Coventry, United Kingdom
A Bailly-Reyre LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France
P Baladron Rodriguez Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
V Balagura Laboratoire Leprince-Ringuet, CNRS/IN2P3, Ecole Polytechnique, Institut Polytechnique de Paris, Palaiseau, France
W Baldini INFN Sezione di Ferrara, Ferrara, Italy
J Baptista de Souza Leite Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
M Barbetti INFN Sezione di Firenze, Firenze, Italy
I R Barbosa Pontifícia Universidade Católica do Rio de Janeiro (PUC-Rio), Rio de Janeiro, Brazil (associated with Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil)
R J Barlow Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
S Barsuk Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
W Barter School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
M Bartolini Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
F Baryshnikov Affiliated with an institute covered by a cooperation agreement with CERN
J M Basels I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
G Bassi INFN Sezione di Pisa, Pisa, Italy
B Batsukh Institute Of High Energy Physics (IHEP), Beijing, China
A Battig Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
A Bay Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
A Beck Department of Physics, University of Warwick, Coventry, United Kingdom
M Becker Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
F Bedeschi INFN Sezione di Pisa, Pisa, Italy
I B Bediaga Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
A Beiter Syracuse University, Syracuse, New York, USA
S Belin Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
V Bellee Physik-Institut, Universität Zürich, Zürich, Switzerland
K Belous Affiliated with an institute covered by a cooperation agreement with CERN
I Belov INFN Sezione di Genova, Genova, Italy
I Belyaev Affiliated with an institute covered by a cooperation agreement with CERN
G Benane Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
G Bencivenni INFN Laboratori Nazionali di Frascati, Frascati, Italy
E Ben-Haim LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France
A Berezhnoy Affiliated with an institute covered by a cooperation agreement with CERN
R Bernet Physik-Institut, Universität Zürich, Zürich, Switzerland
S Bernet Andres DS4DS, La Salle, Universitat Ramon Llull, Barcelona, Spain
H C Bernstein Syracuse University, Syracuse, New York, USA
C Bertella Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
A Bertolin Università degli Studi di Padova, Università e INFN, Padova, Padova, Italy
C Betancourt Physik-Institut, Universität Zürich, Zürich, Switzerland
F Betti School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
J Bex Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
Ia Bezshyiko Physik-Institut, Universität Zürich, Zürich, Switzerland
J Bhom Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
M S Bieker Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
N V Biesuz INFN Sezione di Ferrara, Ferrara, Italy
P Billoir LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France
A Biolchini Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
M Birch Imperial College London, London, United Kingdom
F C R Bishop Université Savoie Mont Blanc, CNRS, IN2P3-LAPP, Annecy, France
A Bitadze Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
A Bizzeti School of Physics and Astronomy, Monash University, Melbourne, Australia Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil Center for High Energy Physics, Tsinghua University, Beijing, China Institute Of High Energy Physics (IHEP), Beijing, China School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China University of Chinese Academy of Sciences, Beijing, China Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China Consejo Nacional de Rectores (CONARE), San Jose, Costa Rica Université Savoie Mont Blanc, CNRS, IN2P3-LAPP, Annecy, France Université Clermont Auvergne, CNRS/IN2P3, LPC, Clermont-Ferrand, France Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France Laboratoire Leprince-Ringuet, CNRS/IN2P3, Ecole Polytechnique, Institut Polytechnique de Paris, Palaiseau, France LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany School of Physics, University College Dublin, Dublin, Ireland INFN Sezione di Bari, Bari, Italy INFN Sezione di Bologna, Bologna, Italy INFN Sezione di Ferrara, Ferrara, Italy INFN Sezione di Firenze, Firenze, Italy INFN Laboratori Nazionali di Frascati, Frascati, Italy INFN Sezione di Genova, Genova, Italy INFN Sezione di Milano, Milano, Italy INFN Sezione di Milano-Bicocca, Milano, Italy INFN Sezione di Cagliari, Monserrato, Italy Università degli Studi di Padova, Università e INFN, Padova, Padova, Italy INFN Sezione di Perugia, Perugia, Italy INFN Sezione di Pisa, Pisa, Italy INFN Sezione di Roma La Sapienza, Roma, Italy INFN Sezione di Roma Tor Vergata, Roma, Italy Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands Nikhef National Institute for Subatomic Physics and VU University Amsterdam, Amsterdam, Netherlands AGH - University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland National Center for Nuclear Research (NCBJ), Warsaw, Poland Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania Affiliated with an institute covered by a cooperation agreement with CERN DS4DS, La Salle, Universitat Ramon Llull, Barcelona, Spain ICCUB, Universitat de Barcelona, Barcelona, Spain Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia - CSIC, Valencia, Spain European Organization for Nuclear Research (CERN), Geneva, Switzerland Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland Physik-Institut, Universität Zürich, Zürich, Switzerland NSC Kharkiv Institute of Physics and Technology (NSC KIPT), Kharkiv, Ukraine Institute for Nuclear Research of the National Academy of Sciences (KINR), Kyiv, Ukraine University of Birmingham, Birmingham, United Kingdom H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom Department of Physics, University of Warwick, Coventry, United Kingdom STFC Rutherford Appleton Laboratory, Didcot, United Kingdom School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom Imperial College London, London, United Kingdom Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom Department of Physics, University of Oxford, Oxford, United Kingdom Massachusetts Institute of Technology, Cambridge, Massachusetts, USA University of Cincinnati, Cincinnati, Ohio, USA University of Maryland, College Park, Maryland, USA Los Alamos National Laboratory (LANL), Los Alamos, New Mexico, USA Syracuse University, Syracuse, New York, USA Pontifícia Universidade Católica do Rio de Janeiro (PUC-Rio), Rio de Janeiro, Brazil (associated with Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil) School of Physics and Electronics, Hunan University, Changsha City, China (associated with Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China) Guangdong Provincial Key Laboratory of Nuclear Science, Guangdong-Hong Kong Joint Laboratory of Quantum Matter, Institute of Quantum Matter, South China Normal University, Guangzhou, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China) Lanzhou University, Lanzhou, China (associated with Institute Of High Energy Physics (IHEP), Beijing, China) School of Physics and Technology, Wuhan University, Wuhan, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China) Departamento de Fisica, Universidad Nacional de Colombia, Bogota, Colombia (associated with LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France) Universität Bonn - Helmholtz-Institut für Strahlen und Kernphysik, Bonn, Germany (associated with Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany) Eotvos Lorand University, Budapest, Hungary (associated with European Organization for Nuclear Research (CERN), Geneva, Switzerland) Van Swinderen Institute, University of Groningen, Groningen, Netherlands (associated with Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands) Universiteit Maastricht, Maastricht, Netherlands (associated with Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands) Tadeusz Kosciuszko Cracow University of Technology, Cracow, Poland (associated with Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland) Department of Physics and Astronomy, Uppsala University, Uppsala, Sweden (associated with School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom) University of Michigan, Ann Arbor, Michigan, USA (associated with Syracuse University, Syracuse, New York, USA) Departement de Physique Nucleaire (SPhN), Gif-Sur-Yvette, France
M P Blago Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
T Blake Department of Physics, University of Warwick, Coventry, United Kingdom
F Blanc Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
J E Blank Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
S Blusk Syracuse University, Syracuse, New York, USA
D Bobulska School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
V Bocharnikov Affiliated with an institute covered by a cooperation agreement with CERN
J A Boelhauve Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
O Boente Garcia Laboratoire Leprince-Ringuet, CNRS/IN2P3, Ecole Polytechnique, Institut Polytechnique de Paris, Palaiseau, France
T Boettcher University of Cincinnati, Cincinnati, Ohio, USA
A Bohare School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
A Boldyrev Affiliated with an institute covered by a cooperation agreement with CERN
C S Bolognani Universiteit Maastricht, Maastricht, Netherlands (associated with Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands)
R Bolzonella INFN Sezione di Ferrara, Ferrara, Italy
N Bondar Affiliated with an institute covered by a cooperation agreement with CERN
F Borgato Università degli Studi di Padova, Università e INFN, Padova, Padova, Italy European Organization for Nuclear Research (CERN), Geneva, Switzerland
S Borghi Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
M Borsato INFN Sezione di Milano-Bicocca, Milano, Italy
J T Borsuk Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
S A Bouchiba Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
T J V Bowcock Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
A Boyer European Organization for Nuclear Research (CERN), Geneva, Switzerland
C Bozzi INFN Sezione di Ferrara, Ferrara, Italy
M J Bradley Imperial College London, London, United Kingdom
S Braun University of Maryland, College Park, Maryland, USA
A Brea Rodriguez Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
N Breer Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
J Brodzicka Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
A Brossa Gonzalo Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
J Brown Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
D Brundu INFN Sezione di Cagliari, Monserrato, Italy
A Buonaura Physik-Institut, Universität Zürich, Zürich, Switzerland
L Buonincontri Università degli Studi di Padova, Università e INFN, Padova, Padova, Italy
A T Burke Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
C Burr European Organization for Nuclear Research (CERN), Geneva, Switzerland
A Bursche Guangdong Provincial Key Laboratory of Nuclear Science, Guangdong-Hong Kong Joint Laboratory of Quantum Matter, Institute of Quantum Matter, South China Normal University, Guangzhou, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China)
A Butkevich Affiliated with an institute covered by a cooperation agreement with CERN
J S Butter Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
J Buytaert European Organization for Nuclear Research (CERN), Geneva, Switzerland
W Byczynski European Organization for Nuclear Research (CERN), Geneva, Switzerland
S Cadeddu INFN Sezione di Cagliari, Monserrato, Italy
H Cai School of Physics and Technology, Wuhan University, Wuhan, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China)
R Calabrese INFN Sezione di Ferrara, Ferrara, Italy
L Calefice Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
S Cali INFN Laboratori Nazionali di Frascati, Frascati, Italy
M Calvi INFN Sezione di Milano-Bicocca, Milano, Italy
M Calvo Gomez DS4DS, La Salle, Universitat Ramon Llull, Barcelona, Spain
J Cambon Bouzas Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
P Campana INFN Laboratori Nazionali di Frascati, Frascati, Italy
D H Campora Perez Universiteit Maastricht, Maastricht, Netherlands (associated with Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands)
A F Campoverde Quezada University of Chinese Academy of Sciences, Beijing, China
S Capelli INFN Sezione di Milano-Bicocca, Milano, Italy
L Capriotti INFN Sezione di Ferrara, Ferrara, Italy
R Caravaca-Mora Consejo Nacional de Rectores (CONARE), San Jose, Costa Rica
A Carbone INFN Sezione di Bologna, Bologna, Italy
L Carcedo Salgado Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
R Cardinale INFN Sezione di Genova, Genova, Italy
A Cardini INFN Sezione di Cagliari, Monserrato, Italy
P Carniti INFN Sezione di Milano-Bicocca, Milano, Italy
L Carus Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
A Casais Vidal Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
R Caspary Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
G Casse Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
J Castro Godinez Consejo Nacional de Rectores (CONARE), San Jose, Costa Rica
M Cattaneo European Organization for Nuclear Research (CERN), Geneva, Switzerland
G Cavallero INFN Sezione di Ferrara, Ferrara, Italy
V Cavallini INFN Sezione di Ferrara, Ferrara, Italy
S Celani Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
J Cerasoli Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
D Cervenkov Department of Physics, University of Oxford, Oxford, United Kingdom
S Cesare INFN Sezione di Milano, Milano, Italy
A J Chadwick Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
I Chahrour University of Michigan, Ann Arbor, Michigan, USA (associated with Syracuse University, Syracuse, New York, USA)
M Charles LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France
Ph Charpentier European Organization for Nuclear Research (CERN), Geneva, Switzerland
C A Chavez Barajas Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
M Chefdeville Université Savoie Mont Blanc, CNRS, IN2P3-LAPP, Annecy, France
C Chen Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
S Chen Institute Of High Energy Physics (IHEP), Beijing, China
A Chernov Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
S Chernyshenko Institute for Nuclear Research of the National Academy of Sciences (KINR), Kyiv, Ukraine
V Chobanova Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
S Cholak Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
M Chrzaszcz Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
A Chubykin Affiliated with an institute covered by a cooperation agreement with CERN
V Chulikov Affiliated with an institute covered by a cooperation agreement with CERN
P Ciambrone INFN Laboratori Nazionali di Frascati, Frascati, Italy
M F Cicala Department of Physics, University of Warwick, Coventry, United Kingdom
X Cid Vidal Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
G Ciezarek European Organization for Nuclear Research (CERN), Geneva, Switzerland
P Cifra European Organization for Nuclear Research (CERN), Geneva, Switzerland
P E L Clarke School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
M Clemencic European Organization for Nuclear Research (CERN), Geneva, Switzerland
H V Cliff Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
J Closier European Organization for Nuclear Research (CERN), Geneva, Switzerland
J L Cobbledick Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
C Cocha Toapaxi Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
V Coco European Organization for Nuclear Research (CERN), Geneva, Switzerland
J Cogan Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
E Cogneras Université Clermont Auvergne, CNRS/IN2P3, LPC, Clermont-Ferrand, France
L Cojocariu Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
P Collins European Organization for Nuclear Research (CERN), Geneva, Switzerland
T Colombo European Organization for Nuclear Research (CERN), Geneva, Switzerland
A Comerma-Montells ICCUB, Universitat de Barcelona, Barcelona, Spain
L Congedo INFN Sezione di Bari, Bari, Italy
A Contu INFN Sezione di Cagliari, Monserrato, Italy
N Cooke School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
I Corredoira Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
A Correia LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France
G Corti European Organization for Nuclear Research (CERN), Geneva, Switzerland
J J Cottee Meldrum H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
B Couturier European Organization for Nuclear Research (CERN), Geneva, Switzerland
D C Craik Physik-Institut, Universität Zürich, Zürich, Switzerland
M Cruz Torres Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
R Currie School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
C L Da Silva Los Alamos National Laboratory (LANL), Los Alamos, New Mexico, USA
S Dadabaev Affiliated with an institute covered by a cooperation agreement with CERN
L Dai School of Physics and Electronics, Hunan University, Changsha City, China (associated with Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China)
X Dai School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
E Dall'Occo Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
J Dalseno Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
C D'Ambrosio European Organization for Nuclear Research (CERN), Geneva, Switzerland
J Daniel Université Clermont Auvergne, CNRS/IN2P3, LPC, Clermont-Ferrand, France
A Danilina Affiliated with an institute covered by a cooperation agreement with CERN
P d'Argent INFN Sezione di Bari, Bari, Italy
A Davidson Department of Physics, University of Warwick, Coventry, United Kingdom
J E Davies Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
A Davis Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
O De Aguiar Francisco Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
C De Angelis INFN Sezione di Cagliari, Monserrato, Italy
J de Boer Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
K De Bruyn Van Swinderen Institute, University of Groningen, Groningen, Netherlands (associated with Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands)
S De Capua Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
M De Cian Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany European Organization for Nuclear Research (CERN), Geneva, Switzerland
U De Freitas Carneiro Da Graca Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
E De Lucia INFN Laboratori Nazionali di Frascati, Frascati, Italy
J M De Miranda Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
L De Paula Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
M De Serio INFN Sezione di Bari, Bari, Italy
D De Simone Physik-Institut, Universität Zürich, Zürich, Switzerland
P De Simone INFN Laboratori Nazionali di Frascati, Frascati, Italy
F De Vellis Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
J A de Vries Universiteit Maastricht, Maastricht, Netherlands (associated with Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands)
F Debernardis INFN Sezione di Bari, Bari, Italy
D Decamp Université Savoie Mont Blanc, CNRS, IN2P3-LAPP, Annecy, France
V Dedu Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
L Del Buono LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France
B Delaney Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
H-P Dembinski Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
J Deng Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China
V Denysenko Physik-Institut, Universität Zürich, Zürich, Switzerland
O Deschamps Université Clermont Auvergne, CNRS/IN2P3, LPC, Clermont-Ferrand, France
F Dettori INFN Sezione di Cagliari, Monserrato, Italy
B Dey Eotvos Lorand University, Budapest, Hungary (associated with European Organization for Nuclear Research (CERN), Geneva, Switzerland)
P Di Nezza INFN Laboratori Nazionali di Frascati, Frascati, Italy
I Diachkov Affiliated with an institute covered by a cooperation agreement with CERN
S Didenko Affiliated with an institute covered by a cooperation agreement with CERN
S Ding Syracuse University, Syracuse, New York, USA
V Dobishuk Institute for Nuclear Research of the National Academy of Sciences (KINR), Kyiv, Ukraine
A D Docheva School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
A Dolmatov Affiliated with an institute covered by a cooperation agreement with CERN
C Dong Center for High Energy Physics, Tsinghua University, Beijing, China
A M Donohoe School of Physics, University College Dublin, Dublin, Ireland
F Dordei INFN Sezione di Cagliari, Monserrato, Italy
A C Dos Reis Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
L Douglas School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
A G Downes Université Savoie Mont Blanc, CNRS, IN2P3-LAPP, Annecy, France
W Duan Guangdong Provincial Key Laboratory of Nuclear Science, Guangdong-Hong Kong Joint Laboratory of Quantum Matter, Institute of Quantum Matter, South China Normal University, Guangzhou, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China)
P Duda Tadeusz Kosciuszko Cracow University of Technology, Cracow, Poland (associated with Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland)
M W Dudek Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
L Dufour European Organization for Nuclear Research (CERN), Geneva, Switzerland
V Duk INFN Sezione di Perugia, Perugia, Italy
P Durante European Organization for Nuclear Research (CERN), Geneva, Switzerland
M M Duras Tadeusz Kosciuszko Cracow University of Technology, Cracow, Poland (associated with Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland)
J M Durham Los Alamos National Laboratory (LANL), Los Alamos, New Mexico, USA
A Dziurda Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
A Dzyuba Affiliated with an institute covered by a cooperation agreement with CERN
S Easo European Organization for Nuclear Research (CERN), Geneva, Switzerland STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
E Eckstein Universität Bonn - Helmholtz-Institut für Strahlen und Kernphysik, Bonn, Germany (associated with Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany)
U Egede School of Physics and Astronomy, Monash University, Melbourne, Australia
A Egorychev Affiliated with an institute covered by a cooperation agreement with CERN
V Egorychev Affiliated with an institute covered by a cooperation agreement with CERN
C Eirea Orro Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
S Eisenhardt School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
E Ejopu Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
S Ek-In Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
L Eklund Department of Physics and Astronomy, Uppsala University, Uppsala, Sweden (associated with School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom)
M Elashri University of Cincinnati, Cincinnati, Ohio, USA
J Ellbracht Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
S Ely Imperial College London, London, United Kingdom
A Ene Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
E Epple University of Cincinnati, Cincinnati, Ohio, USA
S Escher I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
J Eschle Physik-Institut, Universität Zürich, Zürich, Switzerland
S Esen Physik-Institut, Universität Zürich, Zürich, Switzerland
T Evans Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
F Fabiano INFN Sezione di Cagliari, Monserrato, Italy European Organization for Nuclear Research (CERN), Geneva, Switzerland
L N Falcao Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
Y Fan University of Chinese Academy of Sciences, Beijing, China
B Fang Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France School of Physics and Technology, Wuhan University, Wuhan, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China)
L Fantini INFN Sezione di Perugia, Perugia, Italy
M Faria Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
K Farmer School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
D Fazzini INFN Sezione di Milano-Bicocca, Milano, Italy
L Felkowski Tadeusz Kosciuszko Cracow University of Technology, Cracow, Poland (associated with Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland)
M Feng Institute Of High Energy Physics (IHEP), Beijing, China University of Chinese Academy of Sciences, Beijing, China
M Feo European Organization for Nuclear Research (CERN), Geneva, Switzerland
M Fernandez Gomez Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
A D Fernez University of Maryland, College Park, Maryland, USA
F Ferrari INFN Sezione di Bologna, Bologna, Italy
F Ferreira Rodrigues Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
S Ferreres Sole Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
M Ferrillo Physik-Institut, Universität Zürich, Zürich, Switzerland
M Ferro-Luzzi European Organization for Nuclear Research (CERN), Geneva, Switzerland
S Filippov Affiliated with an institute covered by a cooperation agreement with CERN
R A Fini INFN Sezione di Bari, Bari, Italy
M Fiorini INFN Sezione di Ferrara, Ferrara, Italy
M Firlej AGH - University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
K M Fischer Department of Physics, University of Oxford, Oxford, United Kingdom
D S Fitzgerald University of Michigan, Ann Arbor, Michigan, USA (associated with Syracuse University, Syracuse, New York, USA)
C Fitzpatrick Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
T Fiutowski AGH - University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
F Fleuret Laboratoire Leprince-Ringuet, CNRS/IN2P3, Ecole Polytechnique, Institut Polytechnique de Paris, Palaiseau, France
M Fontana INFN Sezione di Bologna, Bologna, Italy
F Fontanelli INFN Sezione di Genova, Genova, Italy
L F Foreman Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
R Forty European Organization for Nuclear Research (CERN), Geneva, Switzerland
D Foulds-Holt Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
M Franco Sevilla University of Maryland, College Park, Maryland, USA
M Frank European Organization for Nuclear Research (CERN), Geneva, Switzerland
E Franzoso INFN Sezione di Ferrara, Ferrara, Italy
G Frau Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
C Frei European Organization for Nuclear Research (CERN), Geneva, Switzerland
D A Friday Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
L Frontini INFN Sezione di Milano, Milano, Italy
J Fu University of Chinese Academy of Sciences, Beijing, China
Q Fuehring Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
Y Fujii School of Physics and Astronomy, Monash University, Melbourne, Australia
T Fulghesu LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France
E Gabriel Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
G Galati INFN Sezione di Bari, Bari, Italy
M D Galati Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
A Gallas Torreira Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
D Galli INFN Sezione di Bologna, Bologna, Italy
S Gambetta European Organization for Nuclear Research (CERN), Geneva, Switzerland School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
M Gandelman Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
P Gandini INFN Sezione di Milano, Milano, Italy
H Gao University of Chinese Academy of Sciences, Beijing, China
R Gao Department of Physics, University of Oxford, Oxford, United Kingdom
Y Gao Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China
Y Gao School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
Y Gao Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China
M Garau INFN Sezione di Cagliari, Monserrato, Italy
L M Garcia Martin Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
P Garcia Moreno ICCUB, Universitat de Barcelona, Barcelona, Spain
J García Pardiñas European Organization for Nuclear Research (CERN), Geneva, Switzerland
B Garcia Plana Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
K G Garg Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China
L Garrido ICCUB, Universitat de Barcelona, Barcelona, Spain
C Gaspar European Organization for Nuclear Research (CERN), Geneva, Switzerland
R E Geertsema Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
L L Gerken Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
E Gersabeck Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
M Gersabeck Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
T Gershon Department of Physics, University of Warwick, Coventry, United Kingdom
Z Ghorbanimoghaddam H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
L Giambastiani Università degli Studi di Padova, Università e INFN, Padova, Padova, Italy
F I Giasemis LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France
V Gibson Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
H K Giemza National Center for Nuclear Research (NCBJ), Warsaw, Poland
A L Gilman Department of Physics, University of Oxford, Oxford, United Kingdom
M Giovannetti INFN Laboratori Nazionali di Frascati, Frascati, Italy
A Gioventù ICCUB, Universitat de Barcelona, Barcelona, Spain
P Gironella Gironell ICCUB, Universitat de Barcelona, Barcelona, Spain
C Giugliano INFN Sezione di Ferrara, Ferrara, Italy
M A Giza Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
E L Gkougkousis Imperial College London, London, United Kingdom
F C Glaser Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
V V Gligorov LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France
C Göbel Pontifícia Universidade Católica do Rio de Janeiro (PUC-Rio), Rio de Janeiro, Brazil (associated with Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil)
E Golobardes DS4DS, La Salle, Universitat Ramon Llull, Barcelona, Spain
D Golubkov Affiliated with an institute covered by a cooperation agreement with CERN
A Golutvin Affiliated with an institute covered by a cooperation agreement with CERN European Organization for Nuclear Research (CERN), Geneva, Switzerland Imperial College London, London, United Kingdom
A Gomes Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
S Gomez Fernandez ICCUB, Universitat de Barcelona, Barcelona, Spain
F Goncalves Abrantes Department of Physics, University of Oxford, Oxford, United Kingdom
M Goncerz Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
G Gong Center for High Energy Physics, Tsinghua University, Beijing, China
J A Gooding Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
I V Gorelov Affiliated with an institute covered by a cooperation agreement with CERN
C Gotti INFN Sezione di Milano-Bicocca, Milano, Italy
J P Grabowski Universität Bonn - Helmholtz-Institut für Strahlen und Kernphysik, Bonn, Germany (associated with Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany)
L A Granado Cardoso European Organization for Nuclear Research (CERN), Geneva, Switzerland
E Graugés ICCUB, Universitat de Barcelona, Barcelona, Spain
E Graverini Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
L Grazette Department of Physics, University of Warwick, Coventry, United Kingdom
G Graziani School of Physics and Astronomy, Monash University, Melbourne, Australia Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil Center for High Energy Physics, Tsinghua University, Beijing, China Institute Of High Energy Physics (IHEP), Beijing, China School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China University of Chinese Academy of Sciences, Beijing, China Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China Consejo Nacional de Rectores (CONARE), San Jose, Costa Rica Université Savoie Mont Blanc, CNRS, IN2P3-LAPP, Annecy, France Université Clermont Auvergne, CNRS/IN2P3, LPC, Clermont-Ferrand, France Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France Laboratoire Leprince-Ringuet, CNRS/IN2P3, Ecole Polytechnique, Institut Polytechnique de Paris, Palaiseau, France LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany School of Physics, University College Dublin, Dublin, Ireland INFN Sezione di Bari, Bari, Italy INFN Sezione di Bologna, Bologna, Italy INFN Sezione di Ferrara, Ferrara, Italy INFN Sezione di Firenze, Firenze, Italy INFN Laboratori Nazionali di Frascati, Frascati, Italy INFN Sezione di Genova, Genova, Italy INFN Sezione di Milano, Milano, Italy INFN Sezione di Milano-Bicocca, Milano, Italy INFN Sezione di Cagliari, Monserrato, Italy Università degli Studi di Padova, Università e INFN, Padova, Padova, Italy INFN Sezione di Perugia, Perugia, Italy INFN Sezione di Pisa, Pisa, Italy INFN Sezione di Roma La Sapienza, Roma, Italy INFN Sezione di Roma Tor Vergata, Roma, Italy Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands Nikhef National Institute for Subatomic Physics and VU University Amsterdam, Amsterdam, Netherlands AGH - University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland National Center for Nuclear Research (NCBJ), Warsaw, Poland Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania Affiliated with an institute covered by a cooperation agreement with CERN DS4DS, La Salle, Universitat Ramon Llull, Barcelona, Spain ICCUB, Universitat de Barcelona, Barcelona, Spain Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia - CSIC, Valencia, Spain European Organization for Nuclear Research (CERN), Geneva, Switzerland Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland Physik-Institut, Universität Zürich, Zürich, Switzerland NSC Kharkiv Institute of Physics and Technology (NSC KIPT), Kharkiv, Ukraine Institute for Nuclear Research of the National Academy of Sciences (KINR), Kyiv, Ukraine University of Birmingham, Birmingham, United Kingdom H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom Department of Physics, University of Warwick, Coventry, United Kingdom STFC Rutherford Appleton Laboratory, Didcot, United Kingdom School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom Imperial College London, London, United Kingdom Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom Department of Physics, University of Oxford, Oxford, United Kingdom Massachusetts Institute of Technology, Cambridge, Massachusetts, USA University of Cincinnati, Cincinnati, Ohio, USA University of Maryland, College Park, Maryland, USA Los Alamos National Laboratory (LANL), Los Alamos, New Mexico, USA Syracuse University, Syracuse, New York, USA Pontifícia Universidade Católica do Rio de Janeiro (PUC-Rio), Rio de Janeiro, Brazil (associated with Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil) School of Physics and Electronics, Hunan University, Changsha City, China (associated with Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China) Guangdong Provincial Key Laboratory of Nuclear Science, Guangdong-Hong Kong Joint Laboratory of Quantum Matter, Institute of Quantum Matter, South China Normal University, Guangzhou, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China) Lanzhou University, Lanzhou, China (associated with Institute Of High Energy Physics (IHEP), Beijing, China) School of Physics and Technology, Wuhan University, Wuhan, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China) Departamento de Fisica, Universidad Nacional de Colombia, Bogota, Colombia (associated with LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France) Universität Bonn - Helmholtz-Institut für Strahlen und Kernphysik, Bonn, Germany (associated with Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany) Eotvos Lorand University, Budapest, Hungary (associated with European Organization for Nuclear Research (CERN), Geneva, Switzerland) Van Swinderen Institute, University of Groningen, Groningen, Netherlands (associated with Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands) Universiteit Maastricht, Maastricht, Netherlands (associated with Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands) Tadeusz Kosciuszko Cracow University of Technology, Cracow, Poland (associated with Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland) Department of Physics and Astronomy, Uppsala University, Uppsala, Sweden (associated with School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom) University of Michigan, Ann Arbor, Michigan, USA (associated with Syracuse University, Syracuse, New York, USA) Departement de Physique Nucleaire (SPhN), Gif-Sur-Yvette, France
A T Grecu Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
L M Greeven Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
N A Grieser University of Cincinnati, Cincinnati, Ohio, USA
L Grillo School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
S Gromov Affiliated with an institute covered by a cooperation agreement with CERN
C Gu Laboratoire Leprince-Ringuet, CNRS/IN2P3, Ecole Polytechnique, Institut Polytechnique de Paris, Palaiseau, France
M Guarise INFN Sezione di Ferrara, Ferrara, Italy
M Guittiere Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
V Guliaeva Affiliated with an institute covered by a cooperation agreement with CERN
P A Günther Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
A-K Guseinov Affiliated with an institute covered by a cooperation agreement with CERN
E Gushchin Affiliated with an institute covered by a cooperation agreement with CERN
Y Guz School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China Affiliated with an institute covered by a cooperation agreement with CERN European Organization for Nuclear Research (CERN), Geneva, Switzerland
T Gys European Organization for Nuclear Research (CERN), Geneva, Switzerland
T Hadavizadeh School of Physics and Astronomy, Monash University, Melbourne, Australia
C Hadjivasiliou University of Maryland, College Park, Maryland, USA
G Haefeli Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
C Haen European Organization for Nuclear Research (CERN), Geneva, Switzerland
J Haimberger European Organization for Nuclear Research (CERN), Geneva, Switzerland
M Hajheidari European Organization for Nuclear Research (CERN), Geneva, Switzerland
T Halewood-Leagas Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
M M Halvorsen European Organization for Nuclear Research (CERN), Geneva, Switzerland
P M Hamilton University of Maryland, College Park, Maryland, USA
J Hammerich Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
Q Han Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China
X Han Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
S Hansmann-Menzemer Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
L Hao University of Chinese Academy of Sciences, Beijing, China
N Harnew Department of Physics, University of Oxford, Oxford, United Kingdom
T Harrison Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
M Hartmann Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
C Hasse European Organization for Nuclear Research (CERN), Geneva, Switzerland
J He University of Chinese Academy of Sciences, Beijing, China
K Heijhoff Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
F Hemmer European Organization for Nuclear Research (CERN), Geneva, Switzerland
C Henderson University of Cincinnati, Cincinnati, Ohio, USA
R D L Henderson School of Physics and Astronomy, Monash University, Melbourne, Australia Department of Physics, University of Warwick, Coventry, United Kingdom
A M Hennequin European Organization for Nuclear Research (CERN), Geneva, Switzerland
K Hennessy Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
L Henry Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
J Herd Imperial College London, London, United Kingdom
J Heuel I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
A Hicheur Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
D Hill Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
S E Hollitt Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
J Horswill Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
R Hou Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China
Y Hou Université Savoie Mont Blanc, CNRS, IN2P3-LAPP, Annecy, France
N Howarth Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
J Hu Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
J Hu Guangdong Provincial Key Laboratory of Nuclear Science, Guangdong-Hong Kong Joint Laboratory of Quantum Matter, Institute of Quantum Matter, South China Normal University, Guangzhou, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China)
W Hu School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
X Hu Center for High Energy Physics, Tsinghua University, Beijing, China
W Huang University of Chinese Academy of Sciences, Beijing, China
W Hulsbergen Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
R J Hunter Department of Physics, University of Warwick, Coventry, United Kingdom
M Hushchyn Affiliated with an institute covered by a cooperation agreement with CERN
D Hutchcroft Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
M Idzik AGH - University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
D Ilin Affiliated with an institute covered by a cooperation agreement with CERN
P Ilten University of Cincinnati, Cincinnati, Ohio, USA
A Inglessi Affiliated with an institute covered by a cooperation agreement with CERN
A Iniukhin Affiliated with an institute covered by a cooperation agreement with CERN
A Ishteev Affiliated with an institute covered by a cooperation agreement with CERN
K Ivshin Affiliated with an institute covered by a cooperation agreement with CERN
R Jacobsson European Organization for Nuclear Research (CERN), Geneva, Switzerland
H Jage I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
S J Jaimes Elles Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia - CSIC, Valencia, Spain Departamento de Fisica, Universidad Nacional de Colombia, Bogota, Colombia (associated with LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France)
S Jakobsen European Organization for Nuclear Research (CERN), Geneva, Switzerland
E Jans Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
B K Jashal Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia - CSIC, Valencia, Spain
A Jawahery University of Maryland, College Park, Maryland, USA
V Jevtic Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
E Jiang University of Maryland, College Park, Maryland, USA
X Jiang Institute Of High Energy Physics (IHEP), Beijing, China University of Chinese Academy of Sciences, Beijing, China
Y Jiang University of Chinese Academy of Sciences, Beijing, China
Y J Jiang School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
M John Department of Physics, University of Oxford, Oxford, United Kingdom
D Johnson University of Birmingham, Birmingham, United Kingdom
C R Jones Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
T P Jones Department of Physics, University of Warwick, Coventry, United Kingdom
S Joshi National Center for Nuclear Research (NCBJ), Warsaw, Poland
B Jost European Organization for Nuclear Research (CERN), Geneva, Switzerland
N Jurik European Organization for Nuclear Research (CERN), Geneva, Switzerland
I Juszczak Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
D Kaminaris Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
S Kandybei NSC Kharkiv Institute of Physics and Technology (NSC KIPT), Kharkiv, Ukraine
Y Kang Center for High Energy Physics, Tsinghua University, Beijing, China
M Karacson European Organization for Nuclear Research (CERN), Geneva, Switzerland
D Karpenkov Affiliated with an institute covered by a cooperation agreement with CERN
M Karpov Affiliated with an institute covered by a cooperation agreement with CERN
A M Kauniskangas Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
J W Kautz University of Cincinnati, Cincinnati, Ohio, USA
F Keizer European Organization for Nuclear Research (CERN), Geneva, Switzerland
D M Keller Syracuse University, Syracuse, New York, USA
M Kenzie Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
T Ketel Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
B Khanji Syracuse University, Syracuse, New York, USA
A Kharisova Affiliated with an institute covered by a cooperation agreement with CERN
S Kholodenko INFN Sezione di Pisa, Pisa, Italy
G Khreich Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
T Kirn I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
V S Kirsebom Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
O Kitouni Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
S Klaver Nikhef National Institute for Subatomic Physics and VU University Amsterdam, Amsterdam, Netherlands
N Kleijne INFN Sezione di Pisa, Pisa, Italy
K Klimaszewski National Center for Nuclear Research (NCBJ), Warsaw, Poland
M R Kmiec National Center for Nuclear Research (NCBJ), Warsaw, Poland
S Koliiev Institute for Nuclear Research of the National Academy of Sciences (KINR), Kyiv, Ukraine
L Kolk Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
A Konoplyannikov Affiliated with an institute covered by a cooperation agreement with CERN
P Kopciewicz AGH - University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland European Organization for Nuclear Research (CERN), Geneva, Switzerland
P Koppenburg Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
M Korolev Affiliated with an institute covered by a cooperation agreement with CERN
I Kostiuk Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
O Kot Institute for Nuclear Research of the National Academy of Sciences (KINR), Kyiv, Ukraine
S Kotriakhova School of Physics and Astronomy, Monash University, Melbourne, Australia Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil Center for High Energy Physics, Tsinghua University, Beijing, China Institute Of High Energy Physics (IHEP), Beijing, China School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China University of Chinese Academy of Sciences, Beijing, China Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China Consejo Nacional de Rectores (CONARE), San Jose, Costa Rica Université Savoie Mont Blanc, CNRS, IN2P3-LAPP, Annecy, France Université Clermont Auvergne, CNRS/IN2P3, LPC, Clermont-Ferrand, France Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France Laboratoire Leprince-Ringuet, CNRS/IN2P3, Ecole Polytechnique, Institut Polytechnique de Paris, Palaiseau, France LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany School of Physics, University College Dublin, Dublin, Ireland INFN Sezione di Bari, Bari, Italy INFN Sezione di Bologna, Bologna, Italy INFN Sezione di Ferrara, Ferrara, Italy INFN Sezione di Firenze, Firenze, Italy INFN Laboratori Nazionali di Frascati, Frascati, Italy INFN Sezione di Genova, Genova, Italy INFN Sezione di Milano, Milano, Italy INFN Sezione di Milano-Bicocca, Milano, Italy INFN Sezione di Cagliari, Monserrato, Italy Università degli Studi di Padova, Università e INFN, Padova, Padova, Italy INFN Sezione di Perugia, Perugia, Italy INFN Sezione di Pisa, Pisa, Italy INFN Sezione di Roma La Sapienza, Roma, Italy INFN Sezione di Roma Tor Vergata, Roma, Italy Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands Nikhef National Institute for Subatomic Physics and VU University Amsterdam, Amsterdam, Netherlands AGH - University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland National Center for Nuclear Research (NCBJ), Warsaw, Poland Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania Affiliated with an institute covered by a cooperation agreement with CERN DS4DS, La Salle, Universitat Ramon Llull, Barcelona, Spain ICCUB, Universitat de Barcelona, Barcelona, Spain Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia - CSIC, Valencia, Spain European Organization for Nuclear Research (CERN), Geneva, Switzerland Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland Physik-Institut, Universität Zürich, Zürich, Switzerland NSC Kharkiv Institute of Physics and Technology (NSC KIPT), Kharkiv, Ukraine Institute for Nuclear Research of the National Academy of Sciences (KINR), Kyiv, Ukraine University of Birmingham, Birmingham, United Kingdom H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom Department of Physics, University of Warwick, Coventry, United Kingdom STFC Rutherford Appleton Laboratory, Didcot, United Kingdom School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom Imperial College London, London, United Kingdom Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom Department of Physics, University of Oxford, Oxford, United Kingdom Massachusetts Institute of Technology, Cambridge, Massachusetts, USA University of Cincinnati, Cincinnati, Ohio, USA University of Maryland, College Park, Maryland, USA Los Alamos National Laboratory (LANL), Los Alamos, New Mexico, USA Syracuse University, Syracuse, New York, USA Pontifícia Universidade Católica do Rio de Janeiro (PUC-Rio), Rio de Janeiro, Brazil (associated with Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil) School of Physics and Electronics, Hunan University, Changsha City, China (associated with Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China) Guangdong Provincial Key Laboratory of Nuclear Science, Guangdong-Hong Kong Joint Laboratory of Quantum Matter, Institute of Quantum Matter, South China Normal University, Guangzhou, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China) Lanzhou University, Lanzhou, China (associated with Institute Of High Energy Physics (IHEP), Beijing, China) School of Physics and Technology, Wuhan University, Wuhan, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China) Departamento de Fisica, Universidad Nacional de Colombia, Bogota, Colombia (associated with LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France) Universität Bonn - Helmholtz-Institut für Strahlen und Kernphysik, Bonn, Germany (associated with Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany) Eotvos Lorand University, Budapest, Hungary (associated with European Organization for Nuclear Research (CERN), Geneva, Switzerland) Van Swinderen Institute, University of Groningen, Groningen, Netherlands (associated with Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands) Universiteit Maastricht, Maastricht, Netherlands (associated with Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands) Tadeusz Kosciuszko Cracow University of Technology, Cracow, Poland (associated with Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland) Department of Physics and Astronomy, Uppsala University, Uppsala, Sweden (associated with School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom) University of Michigan, Ann Arbor, Michigan, USA (associated with Syracuse University, Syracuse, New York, USA) Departement de Physique Nucleaire (SPhN), Gif-Sur-Yvette, France
A Kozachuk Affiliated with an institute covered by a cooperation agreement with CERN
P Kravchenko Affiliated with an institute covered by a cooperation agreement with CERN
L Kravchuk Affiliated with an institute covered by a cooperation agreement with CERN
M Kreps Department of Physics, University of Warwick, Coventry, United Kingdom
S Kretzschmar I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
P Krokovny Affiliated with an institute covered by a cooperation agreement with CERN
W Krupa Syracuse University, Syracuse, New York, USA
W Krzemien National Center for Nuclear Research (NCBJ), Warsaw, Poland
J Kubat Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
S Kubis Tadeusz Kosciuszko Cracow University of Technology, Cracow, Poland (associated with Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland)
W Kucewicz Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
M Kucharczyk Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
V Kudryavtsev Affiliated with an institute covered by a cooperation agreement with CERN
E Kulikova Affiliated with an institute covered by a cooperation agreement with CERN
A Kupsc Department of Physics and Astronomy, Uppsala University, Uppsala, Sweden (associated with School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom)
B K Kutsenko Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
D Lacarrere European Organization for Nuclear Research (CERN), Geneva, Switzerland
A Lai INFN Sezione di Cagliari, Monserrato, Italy
A Lampis INFN Sezione di Cagliari, Monserrato, Italy
D Lancierini Physik-Institut, Universität Zürich, Zürich, Switzerland
C Landesa Gomez Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
J J Lane School of Physics and Astronomy, Monash University, Melbourne, Australia
R Lane H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
C Langenbruch Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
J Langer Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
O Lantwin Affiliated with an institute covered by a cooperation agreement with CERN
T Latham Department of Physics, University of Warwick, Coventry, United Kingdom
F Lazzari INFN Sezione di Pisa, Pisa, Italy
C Lazzeroni University of Birmingham, Birmingham, United Kingdom
R Le Gac Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
S H Lee University of Michigan, Ann Arbor, Michigan, USA (associated with Syracuse University, Syracuse, New York, USA)
R Lefèvre Université Clermont Auvergne, CNRS/IN2P3, LPC, Clermont-Ferrand, France
A Leflat Affiliated with an institute covered by a cooperation agreement with CERN
S Legotin Affiliated with an institute covered by a cooperation agreement with CERN
M Lehuraux Department of Physics, University of Warwick, Coventry, United Kingdom
O Leroy Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
T Lesiak Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
B Leverington Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
A Li Center for High Energy Physics, Tsinghua University, Beijing, China
H Li Guangdong Provincial Key Laboratory of Nuclear Science, Guangdong-Hong Kong Joint Laboratory of Quantum Matter, Institute of Quantum Matter, South China Normal University, Guangzhou, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China)
K Li Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China
L Li Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
P Li European Organization for Nuclear Research (CERN), Geneva, Switzerland
P-R Li Lanzhou University, Lanzhou, China (associated with Institute Of High Energy Physics (IHEP), Beijing, China)
S Li Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China
T Li Institute Of High Energy Physics (IHEP), Beijing, China
T Li Guangdong Provincial Key Laboratory of Nuclear Science, Guangdong-Hong Kong Joint Laboratory of Quantum Matter, Institute of Quantum Matter, South China Normal University, Guangzhou, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China)
Y Li Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China
Y Li Institute Of High Energy Physics (IHEP), Beijing, China
Z Li Syracuse University, Syracuse, New York, USA
Z Lian Center for High Energy Physics, Tsinghua University, Beijing, China
X Liang Syracuse University, Syracuse, New York, USA
C Lin University of Chinese Academy of Sciences, Beijing, China
T Lin STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
R Lindner European Organization for Nuclear Research (CERN), Geneva, Switzerland
V Lisovskyi Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
R Litvinov INFN Sezione di Cagliari, Monserrato, Italy
G Liu Guangdong Provincial Key Laboratory of Nuclear Science, Guangdong-Hong Kong Joint Laboratory of Quantum Matter, Institute of Quantum Matter, South China Normal University, Guangzhou, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China)
H Liu University of Chinese Academy of Sciences, Beijing, China
K Liu Lanzhou University, Lanzhou, China (associated with Institute Of High Energy Physics (IHEP), Beijing, China)
Q Liu University of Chinese Academy of Sciences, Beijing, China
S Liu Institute Of High Energy Physics (IHEP), Beijing, China University of Chinese Academy of Sciences, Beijing, China
Y Liu School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
Y Liu Lanzhou University, Lanzhou, China (associated with Institute Of High Energy Physics (IHEP), Beijing, China)
Y L Liu Imperial College London, London, United Kingdom
A Lobo Salvia ICCUB, Universitat de Barcelona, Barcelona, Spain
A Loi INFN Sezione di Cagliari, Monserrato, Italy
J Lomba Castro Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
T Long Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
J H Lopes Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
A Lopez Huertas ICCUB, Universitat de Barcelona, Barcelona, Spain
S López Soliño Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
G H Lovell Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
C Lucarelli INFN Sezione di Firenze, Firenze, Italy
D Lucchesi Università degli Studi di Padova, Università e INFN, Padova, Padova, Italy
S Luchuk Affiliated with an institute covered by a cooperation agreement with CERN
M Lucio Martinez Universiteit Maastricht, Maastricht, Netherlands (associated with Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands)
V Lukashenko Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands Institute for Nuclear Research of the National Academy of Sciences (KINR), Kyiv, Ukraine
Y Luo Center for High Energy Physics, Tsinghua University, Beijing, China
A Lupato Università degli Studi di Padova, Università e INFN, Padova, Padova, Italy
E Luppi INFN Sezione di Ferrara, Ferrara, Italy
K Lynch School of Physics, University College Dublin, Dublin, Ireland
X-R Lyu University of Chinese Academy of Sciences, Beijing, China
G M Ma Center for High Energy Physics, Tsinghua University, Beijing, China
R Ma University of Chinese Academy of Sciences, Beijing, China
S Maccolini Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
F Machefert Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
F Maciuc Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
I Mackay Department of Physics, University of Oxford, Oxford, United Kingdom
L R Madhan Mohan Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
M M Madurai University of Birmingham, Birmingham, United Kingdom
A Maevskiy Affiliated with an institute covered by a cooperation agreement with CERN
D Magdalinski Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
D Maisuzenko Affiliated with an institute covered by a cooperation agreement with CERN
M W Majewski AGH - University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
J J Malczewski Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
S Malde Department of Physics, University of Oxford, Oxford, United Kingdom
B Malecki Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland European Organization for Nuclear Research (CERN), Geneva, Switzerland
L Malentacca European Organization for Nuclear Research (CERN), Geneva, Switzerland
A Malinin Affiliated with an institute covered by a cooperation agreement with CERN
T Maltsev Affiliated with an institute covered by a cooperation agreement with CERN
G Manca INFN Sezione di Cagliari, Monserrato, Italy
G Mancinelli Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
C Mancuso Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France INFN Sezione di Milano, Milano, Italy
R Manera Escalero ICCUB, Universitat de Barcelona, Barcelona, Spain
D Manuzzi INFN Sezione di Bologna, Bologna, Italy
D Marangotto INFN Sezione di Milano, Milano, Italy
J F Marchand Université Savoie Mont Blanc, CNRS, IN2P3-LAPP, Annecy, France
R Marchevski Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
U Marconi INFN Sezione di Bologna, Bologna, Italy
S Mariani European Organization for Nuclear Research (CERN), Geneva, Switzerland
C Marin Benito ICCUB, Universitat de Barcelona, Barcelona, Spain European Organization for Nuclear Research (CERN), Geneva, Switzerland
J Marks Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
A M Marshall H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
P J Marshall Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
G Martelli INFN Sezione di Perugia, Perugia, Italy
G Martellotti INFN Sezione di Roma La Sapienza, Roma, Italy
L Martinazzoli European Organization for Nuclear Research (CERN), Geneva, Switzerland
M Martinelli INFN Sezione di Milano-Bicocca, Milano, Italy
D Martinez Santos Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
F Martinez Vidal Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia - CSIC, Valencia, Spain
A Massafferri Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
M Materok I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
R Matev European Organization for Nuclear Research (CERN), Geneva, Switzerland
A Mathad Physik-Institut, Universität Zürich, Zürich, Switzerland
V Matiunin Affiliated with an institute covered by a cooperation agreement with CERN
C Matteuzzi Syracuse University, Syracuse, New York, USA
K R Mattioli Laboratoire Leprince-Ringuet, CNRS/IN2P3, Ecole Polytechnique, Institut Polytechnique de Paris, Palaiseau, France
A Mauri Imperial College London, London, United Kingdom
E Maurice Laboratoire Leprince-Ringuet, CNRS/IN2P3, Ecole Polytechnique, Institut Polytechnique de Paris, Palaiseau, France
J Mauricio ICCUB, Universitat de Barcelona, Barcelona, Spain
P Mayencourt Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
M Mazurek European Organization for Nuclear Research (CERN), Geneva, Switzerland
M McCann Imperial College London, London, United Kingdom
L Mcconnell School of Physics, University College Dublin, Dublin, Ireland
T H McGrath Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
N T McHugh School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
A McNab Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
R McNulty School of Physics, University College Dublin, Dublin, Ireland
B Meadows University of Cincinnati, Cincinnati, Ohio, USA
G Meier Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
D Melnychuk National Center for Nuclear Research (NCBJ), Warsaw, Poland
M Merk Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands Universiteit Maastricht, Maastricht, Netherlands (associated with Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands)
A Merli INFN Sezione di Milano, Milano, Italy
L Meyer Garcia Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
D Miao Institute Of High Energy Physics (IHEP), Beijing, China University of Chinese Academy of Sciences, Beijing, China
H Miao University of Chinese Academy of Sciences, Beijing, China
M Mikhasenko Universität Bonn - Helmholtz-Institut für Strahlen und Kernphysik, Bonn, Germany (associated with Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany)
D A Milanes Departamento de Fisica, Universidad Nacional de Colombia, Bogota, Colombia (associated with LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France)
A Minotti INFN Sezione di Milano-Bicocca, Milano, Italy
E Minucci Syracuse University, Syracuse, New York, USA
T Miralles Université Clermont Auvergne, CNRS/IN2P3, LPC, Clermont-Ferrand, France
S E Mitchell School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
B Mitreska Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
D S Mitzel Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
A Modak STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
A Mödden Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
R A Mohammed Department of Physics, University of Oxford, Oxford, United Kingdom
R D Moise I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
S Mokhnenko Affiliated with an institute covered by a cooperation agreement with CERN
T Mombächer European Organization for Nuclear Research (CERN), Geneva, Switzerland
M Monk School of Physics and Astronomy, Monash University, Melbourne, Australia Department of Physics, University of Warwick, Coventry, United Kingdom
I A Monroy Departamento de Fisica, Universidad Nacional de Colombia, Bogota, Colombia (associated with LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France)
S Monteil Université Clermont Auvergne, CNRS/IN2P3, LPC, Clermont-Ferrand, France
A Morcillo Gomez Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
G Morello INFN Laboratori Nazionali di Frascati, Frascati, Italy
M J Morello INFN Sezione di Pisa, Pisa, Italy
M P Morgenthaler Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
J Moron AGH - University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
A B Morris European Organization for Nuclear Research (CERN), Geneva, Switzerland
A G Morris Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
R Mountain Syracuse University, Syracuse, New York, USA
H Mu Center for High Energy Physics, Tsinghua University, Beijing, China
Z M Mu School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
E Muhammad Department of Physics, University of Warwick, Coventry, United Kingdom
F Muheim School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
M Mulder Van Swinderen Institute, University of Groningen, Groningen, Netherlands (associated with Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands)
K Müller Physik-Institut, Universität Zürich, Zürich, Switzerland
F Mũnoz-Rojas Consejo Nacional de Rectores (CONARE), San Jose, Costa Rica
R Murta Imperial College London, London, United Kingdom
P Naik Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
T Nakada Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
R Nandakumar STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
T Nanut European Organization for Nuclear Research (CERN), Geneva, Switzerland
I Nasteva Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
M Needham School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
N Neri INFN Sezione di Milano, Milano, Italy
S Neubert Universität Bonn - Helmholtz-Institut für Strahlen und Kernphysik, Bonn, Germany (associated with Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany)
N Neufeld European Organization for Nuclear Research (CERN), Geneva, Switzerland
P Neustroev Affiliated with an institute covered by a cooperation agreement with CERN
R Newcombe Imperial College London, London, United Kingdom
J Nicolini Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
D Nicotra Universiteit Maastricht, Maastricht, Netherlands (associated with Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands)
E M Niel Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
N Nikitin Affiliated with an institute covered by a cooperation agreement with CERN
P Nogga Universität Bonn - Helmholtz-Institut für Strahlen und Kernphysik, Bonn, Germany (associated with Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany)
N S Nolte Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
C Normand Université Savoie Mont Blanc, CNRS, IN2P3-LAPP, Annecy, France INFN Sezione di Cagliari, Monserrato, Italy
J Novoa Fernandez Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
G Nowak University of Cincinnati, Cincinnati, Ohio, USA
C Nunez University of Michigan, Ann Arbor, Michigan, USA (associated with Syracuse University, Syracuse, New York, USA)
H N Nur School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
A Oblakowska-Mucha AGH - University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
V Obraztsov Affiliated with an institute covered by a cooperation agreement with CERN
T Oeser I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
S Okamura INFN Sezione di Ferrara, Ferrara, Italy European Organization for Nuclear Research (CERN), Geneva, Switzerland
R Oldeman INFN Sezione di Cagliari, Monserrato, Italy
F Oliva School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
M Olocco Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
C J G Onderwater Universiteit Maastricht, Maastricht, Netherlands (associated with Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands)
R H O'Neil School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
J M Otalora Goicochea Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
T Ovsiannikova Affiliated with an institute covered by a cooperation agreement with CERN
P Owen Physik-Institut, Universität Zürich, Zürich, Switzerland
A Oyanguren Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia - CSIC, Valencia, Spain
O Ozcelik School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
K O Padeken Universität Bonn - Helmholtz-Institut für Strahlen und Kernphysik, Bonn, Germany (associated with Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany)
B Pagare Department of Physics, University of Warwick, Coventry, United Kingdom
P R Pais Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
T Pajero Department of Physics, University of Oxford, Oxford, United Kingdom
A Palano INFN Sezione di Bari, Bari, Italy
M Palutan INFN Laboratori Nazionali di Frascati, Frascati, Italy
G Panshin Affiliated with an institute covered by a cooperation agreement with CERN
L Paolucci Department of Physics, University of Warwick, Coventry, United Kingdom
A Papanestis STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
M Pappagallo INFN Sezione di Bari, Bari, Italy
L L Pappalardo INFN Sezione di Ferrara, Ferrara, Italy
C Pappenheimer University of Cincinnati, Cincinnati, Ohio, USA
C Parkes Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
B Passalacqua INFN Sezione di Ferrara, Ferrara, Italy
G Passaleva INFN Sezione di Firenze, Firenze, Italy
D Passaro INFN Sezione di Pisa, Pisa, Italy
A Pastore INFN Sezione di Bari, Bari, Italy
M Patel Imperial College London, London, United Kingdom
J Patoc Department of Physics, University of Oxford, Oxford, United Kingdom
C Patrignani INFN Sezione di Bologna, Bologna, Italy
C J Pawley Universiteit Maastricht, Maastricht, Netherlands (associated with Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands)
A Pellegrino Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
M Pepe Altarelli INFN Laboratori Nazionali di Frascati, Frascati, Italy
S Perazzini INFN Sezione di Bologna, Bologna, Italy
D Pereima Affiliated with an institute covered by a cooperation agreement with CERN
A Pereiro Castro Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
P Perret Université Clermont Auvergne, CNRS/IN2P3, LPC, Clermont-Ferrand, France
A Perro European Organization for Nuclear Research (CERN), Geneva, Switzerland
K Petridis H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
A Petrolini INFN Sezione di Genova, Genova, Italy
S Petrucci School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
H Pham Syracuse University, Syracuse, New York, USA
L Pica INFN Sezione di Pisa, Pisa, Italy
M Piccini INFN Sezione di Perugia, Perugia, Italy
B Pietrzyk Université Savoie Mont Blanc, CNRS, IN2P3-LAPP, Annecy, France
G Pietrzyk Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
D Pinci INFN Sezione di Roma La Sapienza, Roma, Italy
F Pisani European Organization for Nuclear Research (CERN), Geneva, Switzerland
M Pizzichemi INFN Sezione di Milano-Bicocca, Milano, Italy
V Placinta Horia Hulubei National Institute of Physics and Nuclear Engineering, Bucharest-Magurele, Romania
M Plo Casasus Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
F Polci LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France European Organization for Nuclear Research (CERN), Geneva, Switzerland
M Poli Lener INFN Laboratori Nazionali di Frascati, Frascati, Italy
A Poluektov Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
N Polukhina Affiliated with an institute covered by a cooperation agreement with CERN
I Polyakov European Organization for Nuclear Research (CERN), Geneva, Switzerland
E Polycarpo Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
S Ponce European Organization for Nuclear Research (CERN), Geneva, Switzerland
D Popov University of Chinese Academy of Sciences, Beijing, China
S Poslavskii Affiliated with an institute covered by a cooperation agreement with CERN
K Prasanth Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
C Prouve Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
V Pugatch Institute for Nuclear Research of the National Academy of Sciences (KINR), Kyiv, Ukraine
V Puill Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
G Punzi INFN Sezione di Pisa, Pisa, Italy
H R Qi Center for High Energy Physics, Tsinghua University, Beijing, China
W Qian University of Chinese Academy of Sciences, Beijing, China
N Qin Center for High Energy Physics, Tsinghua University, Beijing, China
S Qu Center for High Energy Physics, Tsinghua University, Beijing, China
R Quagliani Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
R I Rabadan Trejo Department of Physics, University of Warwick, Coventry, United Kingdom
B Rachwal AGH - University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
J H Rademacker H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
M Rama INFN Sezione di Pisa, Pisa, Italy
M Ramírez García University of Michigan, Ann Arbor, Michigan, USA (associated with Syracuse University, Syracuse, New York, USA)
M Ramos Pernas Department of Physics, University of Warwick, Coventry, United Kingdom
M S Rangel Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
F Ratnikov Affiliated with an institute covered by a cooperation agreement with CERN
G Raven Nikhef National Institute for Subatomic Physics and VU University Amsterdam, Amsterdam, Netherlands
M Rebollo De Miguel Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia - CSIC, Valencia, Spain
F Redi European Organization for Nuclear Research (CERN), Geneva, Switzerland
J Reich H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
F Reiss Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
Z Ren University of Chinese Academy of Sciences, Beijing, China
P K Resmi Department of Physics, University of Oxford, Oxford, United Kingdom
R Ribatti INFN Sezione di Pisa, Pisa, Italy
G R Ricart Laboratoire Leprince-Ringuet, CNRS/IN2P3, Ecole Polytechnique, Institut Polytechnique de Paris, Palaiseau, France Departement de Physique Nucleaire (SPhN), Gif-Sur-Yvette, France
D Riccardi INFN Sezione di Pisa, Pisa, Italy
S Ricciardi STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
K Richardson Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
M Richardson-Slipper School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
K Rinnert Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
P Robbe Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
G Robertson School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
E Rodrigues European Organization for Nuclear Research (CERN), Geneva, Switzerland Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
E Rodriguez Fernandez Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
J A Rodriguez Lopez Departamento de Fisica, Universidad Nacional de Colombia, Bogota, Colombia (associated with LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France)
E Rodriguez Rodriguez Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
A Rogovskiy STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
D L Rolf European Organization for Nuclear Research (CERN), Geneva, Switzerland
A Rollings Department of Physics, University of Oxford, Oxford, United Kingdom
P Roloff European Organization for Nuclear Research (CERN), Geneva, Switzerland
V Romanovskiy Affiliated with an institute covered by a cooperation agreement with CERN
M Romero Lamas Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
A Romero Vidal Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
G Romolini INFN Sezione di Ferrara, Ferrara, Italy
F Ronchetti Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
M Rotondo INFN Laboratori Nazionali di Frascati, Frascati, Italy
S R Roy Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
M S Rudolph Syracuse University, Syracuse, New York, USA
T Ruf European Organization for Nuclear Research (CERN), Geneva, Switzerland
M Ruiz Diaz Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
R A Ruiz Fernandez Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
J Ruiz Vidal Department of Physics and Astronomy, Uppsala University, Uppsala, Sweden (associated with School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom)
A Ryzhikov Affiliated with an institute covered by a cooperation agreement with CERN
J Ryzka AGH - University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
J J Saborido Silva Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
R Sadek Laboratoire Leprince-Ringuet, CNRS/IN2P3, Ecole Polytechnique, Institut Polytechnique de Paris, Palaiseau, France
N Sagidova Affiliated with an institute covered by a cooperation agreement with CERN
N Sahoo University of Birmingham, Birmingham, United Kingdom
B Saitta INFN Sezione di Cagliari, Monserrato, Italy
M Salomoni INFN Sezione di Milano-Bicocca, Milano, Italy
C Sanchez Gras Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
I Sanderswood Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia - CSIC, Valencia, Spain
R Santacesaria INFN Sezione di Roma La Sapienza, Roma, Italy
C Santamarina Rios Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
M Santimaria INFN Laboratori Nazionali di Frascati, Frascati, Italy
L Santoro Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
E Santovetti INFN Sezione di Roma Tor Vergata, Roma, Italy
A Saputi INFN Sezione di Ferrara, Ferrara, Italy European Organization for Nuclear Research (CERN), Geneva, Switzerland
D Saranin Affiliated with an institute covered by a cooperation agreement with CERN
G Sarpis School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
M Sarpis Universität Bonn - Helmholtz-Institut für Strahlen und Kernphysik, Bonn, Germany (associated with Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany)
A Sarti INFN Sezione di Roma La Sapienza, Roma, Italy
C Satriano INFN Sezione di Roma La Sapienza, Roma, Italy
A Satta INFN Sezione di Roma Tor Vergata, Roma, Italy
M Saur School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
D Savrina Affiliated with an institute covered by a cooperation agreement with CERN
H Sazak Université Clermont Auvergne, CNRS/IN2P3, LPC, Clermont-Ferrand, France
L G Scantlebury Smead Department of Physics, University of Oxford, Oxford, United Kingdom
A Scarabotto LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France
S Schael I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
S Scherl Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
A M Schertz Eotvos Lorand University, Budapest, Hungary (associated with European Organization for Nuclear Research (CERN), Geneva, Switzerland)
M Schiller School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
H Schindler European Organization for Nuclear Research (CERN), Geneva, Switzerland
M Schmelling Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
B Schmidt European Organization for Nuclear Research (CERN), Geneva, Switzerland
S Schmitt I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
H Schmitz Universität Bonn - Helmholtz-Institut für Strahlen und Kernphysik, Bonn, Germany (associated with Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany)
O Schneider Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
A Schopper European Organization for Nuclear Research (CERN), Geneva, Switzerland
N Schulte Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
S Schulte Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
M H Schune Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
R Schwemmer European Organization for Nuclear Research (CERN), Geneva, Switzerland
G Schwering I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany
B Sciascia INFN Laboratori Nazionali di Frascati, Frascati, Italy
A Sciuccati European Organization for Nuclear Research (CERN), Geneva, Switzerland
S Sellam Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
A Semennikov Affiliated with an institute covered by a cooperation agreement with CERN
M Senghi Soares Nikhef National Institute for Subatomic Physics and VU University Amsterdam, Amsterdam, Netherlands
A Sergi INFN Sezione di Genova, Genova, Italy
N Serra European Organization for Nuclear Research (CERN), Geneva, Switzerland Physik-Institut, Universität Zürich, Zürich, Switzerland
L Sestini Università degli Studi di Padova, Università e INFN, Padova, Padova, Italy
A Seuthe Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
Y Shang School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
D M Shangase University of Michigan, Ann Arbor, Michigan, USA (associated with Syracuse University, Syracuse, New York, USA)
M Shapkin Affiliated with an institute covered by a cooperation agreement with CERN
I Shchemerov Affiliated with an institute covered by a cooperation agreement with CERN
L Shchutska Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
T Shears Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
L Shekhtman Affiliated with an institute covered by a cooperation agreement with CERN
Z Shen School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
S Sheng Institute Of High Energy Physics (IHEP), Beijing, China University of Chinese Academy of Sciences, Beijing, China
V Shevchenko Affiliated with an institute covered by a cooperation agreement with CERN
B Shi University of Chinese Academy of Sciences, Beijing, China
E B Shields INFN Sezione di Milano-Bicocca, Milano, Italy
Y Shimizu Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
E Shmanin Affiliated with an institute covered by a cooperation agreement with CERN
R Shorkin Affiliated with an institute covered by a cooperation agreement with CERN
J D Shupperd Syracuse University, Syracuse, New York, USA
R Silva Coutinho Syracuse University, Syracuse, New York, USA
G Simi Università degli Studi di Padova, Università e INFN, Padova, Padova, Italy
S Simone INFN Sezione di Bari, Bari, Italy
N Skidmore Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
R Skuza Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
T Skwarnicki Syracuse University, Syracuse, New York, USA
M W Slater University of Birmingham, Birmingham, United Kingdom
J C Smallwood Department of Physics, University of Oxford, Oxford, United Kingdom
E Smith Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
K Smith Los Alamos National Laboratory (LANL), Los Alamos, New Mexico, USA
M Smith Imperial College London, London, United Kingdom
A Snoch Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
L Soares Lavra School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
M D Sokoloff University of Cincinnati, Cincinnati, Ohio, USA
F J P Soler School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
A Solomin Affiliated with an institute covered by a cooperation agreement with CERN H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
A Solovev Affiliated with an institute covered by a cooperation agreement with CERN
I Solovyev Affiliated with an institute covered by a cooperation agreement with CERN
R Song School of Physics and Astronomy, Monash University, Melbourne, Australia
Y Song Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
Y Song Center for High Energy Physics, Tsinghua University, Beijing, China
Y S Song School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
F L Souza De Almeida Syracuse University, Syracuse, New York, USA
B Souza De Paula Universidade Federal do Rio de Janeiro (UFRJ), Rio de Janeiro, Brazil
E Spadaro Norella INFN Sezione di Milano, Milano, Italy
E Spedicato INFN Sezione di Bologna, Bologna, Italy
J G Speer Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
E Spiridenkov Affiliated with an institute covered by a cooperation agreement with CERN
P Spradlin School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
V Sriskaran European Organization for Nuclear Research (CERN), Geneva, Switzerland
F Stagni European Organization for Nuclear Research (CERN), Geneva, Switzerland
M Stahl European Organization for Nuclear Research (CERN), Geneva, Switzerland
S Stahl European Organization for Nuclear Research (CERN), Geneva, Switzerland
S Stanislaus Department of Physics, University of Oxford, Oxford, United Kingdom
E N Stein European Organization for Nuclear Research (CERN), Geneva, Switzerland
O Steinkamp Physik-Institut, Universität Zürich, Zürich, Switzerland
O Stenyakin Affiliated with an institute covered by a cooperation agreement with CERN
H Stevens Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
D Strekalina Affiliated with an institute covered by a cooperation agreement with CERN
Y Su University of Chinese Academy of Sciences, Beijing, China
F Suljik Department of Physics, University of Oxford, Oxford, United Kingdom
J Sun INFN Sezione di Cagliari, Monserrato, Italy
L Sun School of Physics and Technology, Wuhan University, Wuhan, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China)
Y Sun University of Maryland, College Park, Maryland, USA
P N Swallow University of Birmingham, Birmingham, United Kingdom
K Swientek AGH - University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
F Swystun Department of Physics, University of Warwick, Coventry, United Kingdom
A Szabelski National Center for Nuclear Research (NCBJ), Warsaw, Poland
T Szumlak AGH - University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
M Szymanski European Organization for Nuclear Research (CERN), Geneva, Switzerland
Y Tan Center for High Energy Physics, Tsinghua University, Beijing, China
S Taneja Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
M D Tat Department of Physics, University of Oxford, Oxford, United Kingdom
A Terentev Physik-Institut, Universität Zürich, Zürich, Switzerland
F Terzuoli INFN Sezione di Pisa, Pisa, Italy
F Teubert European Organization for Nuclear Research (CERN), Geneva, Switzerland
E Thomas European Organization for Nuclear Research (CERN), Geneva, Switzerland
D J D Thompson University of Birmingham, Birmingham, United Kingdom
H Tilquin Imperial College London, London, United Kingdom
V Tisserand Université Clermont Auvergne, CNRS/IN2P3, LPC, Clermont-Ferrand, France
S T'Jampens Université Savoie Mont Blanc, CNRS, IN2P3-LAPP, Annecy, France
M Tobin Institute Of High Energy Physics (IHEP), Beijing, China
L Tomassetti INFN Sezione di Ferrara, Ferrara, Italy
G Tonani INFN Sezione di Milano, Milano, Italy
X Tong School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
D Torres Machado Centro Brasileiro de Pesquisas Físicas (CBPF), Rio de Janeiro, Brazil
L Toscano Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
D Y Tou Center for High Energy Physics, Tsinghua University, Beijing, China
C Trippl DS4DS, La Salle, Universitat Ramon Llull, Barcelona, Spain
G Tuci Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
N Tuning Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
L H Uecker Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
A Ukleja AGH - University of Science and Technology, Faculty of Physics and Applied Computer Science, Kraków, Poland
D J Unverzagt Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
E Ursov Affiliated with an institute covered by a cooperation agreement with CERN
A Usachov Nikhef National Institute for Subatomic Physics and VU University Amsterdam, Amsterdam, Netherlands
A Ustyuzhanin Affiliated with an institute covered by a cooperation agreement with CERN
U Uwer Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
V Vagnoni INFN Sezione di Bologna, Bologna, Italy
A Valassi European Organization for Nuclear Research (CERN), Geneva, Switzerland
G Valenti INFN Sezione di Bologna, Bologna, Italy
N Valls Canudas DS4DS, La Salle, Universitat Ramon Llull, Barcelona, Spain
H Van Hecke Los Alamos National Laboratory (LANL), Los Alamos, New Mexico, USA
E van Herwijnen Imperial College London, London, United Kingdom
C B Van Hulse Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
R Van Laak Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
M van Veghel Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands
R Vazquez Gomez ICCUB, Universitat de Barcelona, Barcelona, Spain
P Vazquez Regueiro Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
C Vázquez Sierra Instituto Galego de Física de Altas Enerxías (IGFAE), Universidade de Santiago de Compostela, Santiago de Compostela, Spain
S Vecchi INFN Sezione di Ferrara, Ferrara, Italy
J J Velthuis H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
M Veltri INFN Sezione di Firenze, Firenze, Italy
A Venkateswaran Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
M Vesterinen Department of Physics, University of Warwick, Coventry, United Kingdom
D Vieira University of Cincinnati, Cincinnati, Ohio, USA
M Vieites Diaz European Organization for Nuclear Research (CERN), Geneva, Switzerland
X Vilasis-Cardona DS4DS, La Salle, Universitat Ramon Llull, Barcelona, Spain
E Vilella Figueras Oliver Lodge Laboratory, University of Liverpool, Liverpool, United Kingdom
A Villa INFN Sezione di Bologna, Bologna, Italy
P Vincent LPNHE, Sorbonne Université, Paris Diderot Sorbonne Paris Cité, CNRS/IN2P3, Paris, France
F C Volle Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
D Vom Bruch Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
V Vorobyev Affiliated with an institute covered by a cooperation agreement with CERN
N Voropaev Affiliated with an institute covered by a cooperation agreement with CERN
K Vos Universiteit Maastricht, Maastricht, Netherlands (associated with Nikhef National Institute for Subatomic Physics, Amsterdam, Netherlands)
G Vouters Université Savoie Mont Blanc, CNRS, IN2P3-LAPP, Annecy, France
C Vrahas School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
J Walsh INFN Sezione di Pisa, Pisa, Italy
E J Walton School of Physics and Astronomy, Monash University, Melbourne, Australia
G Wan School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
C Wang Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
G Wang Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China
J Wang School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
J Wang Institute Of High Energy Physics (IHEP), Beijing, China
J Wang Center for High Energy Physics, Tsinghua University, Beijing, China
J Wang School of Physics and Technology, Wuhan University, Wuhan, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China)
M Wang INFN Sezione di Milano, Milano, Italy
N W Wang University of Chinese Academy of Sciences, Beijing, China
R Wang H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
X Wang Guangdong Provincial Key Laboratory of Nuclear Science, Guangdong-Hong Kong Joint Laboratory of Quantum Matter, Institute of Quantum Matter, South China Normal University, Guangzhou, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China)
X W Wang Imperial College London, London, United Kingdom
Y Wang Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China
Z Wang Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
Z Wang Center for High Energy Physics, Tsinghua University, Beijing, China
Z Wang University of Chinese Academy of Sciences, Beijing, China
J A Ward School of Physics and Astronomy, Monash University, Melbourne, Australia Department of Physics, University of Warwick, Coventry, United Kingdom
N K Watson University of Birmingham, Birmingham, United Kingdom
D Websdale Imperial College London, London, United Kingdom
Y Wei School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
B D C Westhenry H.H. Wills Physics Laboratory, University of Bristol, Bristol, United Kingdom
D J White Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
M Whitehead School of Physics and Astronomy, University of Glasgow, Glasgow, United Kingdom
A R Wiederhold Department of Physics, University of Warwick, Coventry, United Kingdom
D Wiedner Fakultät Physik, Technische Universität Dortmund, Dortmund, Germany
G Wilkinson Department of Physics, University of Oxford, Oxford, United Kingdom
M K Wilkinson University of Cincinnati, Cincinnati, Ohio, USA
M Williams Massachusetts Institute of Technology, Cambridge, Massachusetts, USA
M R J Williams School of Physics and Astronomy, University of Edinburgh, Edinburgh, United Kingdom
R Williams Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
F F Wilson STFC Rutherford Appleton Laboratory, Didcot, United Kingdom
W Wislicki National Center for Nuclear Research (NCBJ), Warsaw, Poland
M Witek Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
L Witola Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
C P Wong Los Alamos National Laboratory (LANL), Los Alamos, New Mexico, USA
G Wormser Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
S A Wotton Cavendish Laboratory, University of Cambridge, Cambridge, United Kingdom
H Wu Syracuse University, Syracuse, New York, USA
J Wu Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China
Y Wu School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
K Wyllie European Organization for Nuclear Research (CERN), Geneva, Switzerland
S Xian Guangdong Provincial Key Laboratory of Nuclear Science, Guangdong-Hong Kong Joint Laboratory of Quantum Matter, Institute of Quantum Matter, South China Normal University, Guangzhou, China (associated with Center for High Energy Physics, Tsinghua University, Beijing, China)
Z Xiang Institute Of High Energy Physics (IHEP), Beijing, China
Y Xie Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China
A Xu INFN Sezione di Pisa, Pisa, Italy
J Xu University of Chinese Academy of Sciences, Beijing, China
L Xu Center for High Energy Physics, Tsinghua University, Beijing, China
L Xu Center for High Energy Physics, Tsinghua University, Beijing, China
M Xu Department of Physics, University of Warwick, Coventry, United Kingdom
Z Xu Université Clermont Auvergne, CNRS/IN2P3, LPC, Clermont-Ferrand, France
Z Xu University of Chinese Academy of Sciences, Beijing, China
Z Xu Institute Of High Energy Physics (IHEP), Beijing, China
D Yang Center for High Energy Physics, Tsinghua University, Beijing, China
S Yang University of Chinese Academy of Sciences, Beijing, China
X Yang School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
Y Yang INFN Sezione di Genova, Genova, Italy
Z Yang School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
Z Yang University of Maryland, College Park, Maryland, USA
V Yeroshenko Université Paris-Saclay, CNRS/IN2P3, IJCLab, Orsay, France
H Yeung Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom
H Yin Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China
C Y Yu School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
J Yu School of Physics and Electronics, Hunan University, Changsha City, China (associated with Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China)
X Yuan Institute Of High Energy Physics (IHEP), Beijing, China
E Zaffaroni Institute of Physics, Ecole Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland
M Zavertyaev Max-Planck-Institut für Kernphysik (MPIK), Heidelberg, Germany
M Zdybal Henryk Niewodniczanski Institute of Nuclear Physics Polish Academy of Sciences, Kraków, Poland
M Zeng Center for High Energy Physics, Tsinghua University, Beijing, China
C Zhang School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
D Zhang Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China
J Zhang University of Chinese Academy of Sciences, Beijing, China
L Zhang Center for High Energy Physics, Tsinghua University, Beijing, China
S Zhang School of Physics and Electronics, Hunan University, Changsha City, China (associated with Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China)
S Zhang School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
Y Zhang School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
Y Zhang Department of Physics, University of Oxford, Oxford, United Kingdom
Y Z Zhang Center for High Energy Physics, Tsinghua University, Beijing, China
Y Zhao Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
A Zharkova Affiliated with an institute covered by a cooperation agreement with CERN
A Zhelezov Physikalisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg, Germany
X Z Zheng Center for High Energy Physics, Tsinghua University, Beijing, China
Y Zheng University of Chinese Academy of Sciences, Beijing, China
T Zhou School of Physics State Key Laboratory of Nuclear Physics and Technology, Peking University, Beijing, China
X Zhou Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China
Y Zhou University of Chinese Academy of Sciences, Beijing, China
V Zhovkovska Department of Physics, University of Warwick, Coventry, United Kingdom
L Z Zhu University of Chinese Academy of Sciences, Beijing, China
X Zhu Center for High Energy Physics, Tsinghua University, Beijing, China
X Zhu Institute of Particle Physics, Central China Normal University, Wuhan, Hubei, China
Z Zhu University of Chinese Academy of Sciences, Beijing, China
V Zhukov I. Physikalisches Institut, RWTH Aachen University, Aachen, Germany Affiliated with an institute covered by a cooperation agreement with CERN
J Zhuo Instituto de Fisica Corpuscular, Centro Mixto Universidad de Valencia - CSIC, Valencia, Spain
Q Zou Institute Of High Energy Physics (IHEP), Beijing, China University of Chinese Academy of Sciences, Beijing, China
D Zuliani Università degli Studi di Padova, Università e INFN, Padova, Padova, Italy
G Zunica Department of Physics and Astronomy, University of Manchester, Manchester, United Kingdom

Collapse

Association between infarct location and haemorrhagic transformation of acute ischaemic stroke after intravenous thrombolysis

AIM

To evaluate the association between computed tomography (CT)-based imaging variables at the time of admission and haemorrhagic transformation (HT) after intravenous thrombolysis (IVT).

MATERIALS AND METHODS

One hundred and eight patients who were treated with IVT for acute ischaemic stroke (AIS) during January 2021 to July 2023 were analysed retrospectively. The infarct location was classified as cortical or subcortical in accordance with the Alberta Stroke Program Early CT Score (ASPECTS) system. Logistic regression and receiver operating characteristic curve analyses were performed to determine the relationship between ischaemic variables and HT.

RESULTS

Of the total, 18 (16.7%) patients had HT and seven (6.5%) had symptomatic intracerebral haemorrhage (sICH). Multivariate analysis revealed that cortical ASPECTS was independently associated with HT (odds ratio [OR], 0.197; 95% confidence interval [CI], 0.076-0.511; p=0.001) and cortical ASPECTS was independently associated with sICH (OR, 0.066; 95% CI, 0.009-0.510; p=0.009). To predict HT and sICH, cortical ASPECTS (HT area under the curve [AUC] = 0.881, sICH AUC = 0.971) provided a higher AUC compared with ASPECTS (HT AUC = 0.850, sICH AUC = 0.918).

CONCLUSION

Cortical ASPECTS seen on CT at the time of admission is associated with HT and sICH after IVT.

In ovo injection of AZD6244 suppresses feather follicle development by the inhibition of ERK and Wnt/β-catenin pathways in goose embryos (Anser cygnoides)

1. Feathers are an important product from poultry, and the state of feather growth and development plays an important role in their economic value.2. In total, 120 eggs were selected for immunoblotting and immunolocalisation experiments of ERK and β-catenin proteins in different developmental stages of goose embryos. The ERK protein was highly expressed in the early stage of goose embryo development, while β-catenin protein was highly expressed in the middle stage of embryo development.3. The 120 eggs were divided into four treatment groups, including an uninjected group (BLANK), a group injected with 100 µl of cosolvent (CK), a group injected with 100 µl of AZD6244 containing cosolvent in a dose of 5 mg/kg AZD6244 containing cosolvent (AZD5) and a group injected with 100 µl of AZD6244 containing cosolvent in a dose of 15 mg/kg AZD6244 containing cosolvent (AZD15). The eggs were injected on the ninth day of embryonic development (E9). Samples were collected at E21.5 to observe feather width, feather follicle diameter, ERK and Wnt/β-catenin pathway protein expression.4. The AZD5 and AZD15 doses were within the embryonic safety range compared to the BLANK and CK groups and had no significant effect on the survival rate and weight at the inflection point, but significantly reduced the feather width and feather follicle diameter (p < 0.05). The AZD6244 treatment inhibited ERK protein phosphorylation levels and blocked the Wnt/β-catenin pathway, which in turn significantly down-regulated the expression levels of FZD4, β-catenin, TCF4 and LEF1 (p < 0.05), with an inhibitory effect in the AZD15 group being more significant. The immunohistochemical results of β-catenin and p-ERK were consistent with Western blot results.5. The small molecule inhibitor AZD6244 regulated the growth and development of feather follicles in goose embryos by the ERK and Wnt/β-catenin pathways.

Observation of Cabibbo-Suppressed Two-Body Hadronic Decays and Precision Mass Measurement of the Ω_{c}^{0} Baryon

The first observation of the singly Cabibbo-suppressed Ω_{c}^{0}→Ω^{-}K^{+} and Ω_{c}^{0}→Ξ^{-}π^{+} decays is reported, using proton-proton collision data at a center-of-mass energy of 13 TeV, corresponding to an integrated luminosity of 5.4  fb^{-1}, collected with the LHCb detector between 2016 and 2018. The branching fraction ratios are measured to be B(Ω_{c}^{0}→Ω^{-}K^{+})/B(Ω_{c}^{0}→Ω^{-}π^{+})=[6.08±0.51(stat)±0.40(syst)]%,B(Ω_{c}^{0}→Ξ^{-}π^{+})/B(Ω_{c}^{0}→Ω^{-}π^{+})=[15.81±0.87(stat)±0.44(syst)±0.16(ext)]%. In addition, using the Ω_{c}^{0}→Ω^{-}π^{+} decay channel, the Ω_{c}^{0} baryon mass is measured to be M(Ω_{c}^{0})=2695.28±0.07(stat)±0.27(syst)±0.30(ext)  MeV, improving the precision of the previous world average by a factor of 4.

Enhanced Production of Λ_{b}^{0} Baryons in High-Multiplicity pp Collisions at sqrt[s]=13 TeV

The production rate of Λ_{b}^{0} baryons relative to B^{0} mesons in pp collisions at a center-of-mass energy sqrt[s]=13  TeV is measured by the LHCb experiment. The ratio of Λ_{b}^{0} to B^{0} production cross sections shows a significant dependence on both the transverse momentum and the measured charged-particle multiplicity. At low multiplicity, the ratio measured at LHCb is consistent with the value measured in e^{+}e^{-} collisions, and increases by a factor of ∼2 with increasing multiplicity. At relatively low transverse momentum, the ratio of Λ_{b}^{0} to B^{0} cross sections is higher than what is measured in e^{+}e^{-} collisions, but converges with the e^{+}e^{-} ratio as the momentum increases. These results imply that the evolution of heavy b quarks into final-state hadrons is influenced by the density of the hadronic environment produced in the collision. Comparisons with several models and implications for the mechanisms enforcing quark confinement are discussed.

Achievement of Target Gain Larger than Unity in an Inertial Fusion Experiment

On December 5, 2022, an indirect drive fusion implosion on the National Ignition Facility (NIF) achieved a target gain G_{target} of 1.5. This is the first laboratory demonstration of exceeding "scientific breakeven" (or G_{target}>1) where 2.05 MJ of 351 nm laser light produced 3.1 MJ of total fusion yield, a result which significantly exceeds the Lawson criterion for fusion ignition as reported in a previous NIF implosion [H. Abu-Shawareb et al. (Indirect Drive ICF Collaboration), Phys. Rev. Lett. 129, 075001 (2022)PRLTAO0031-900710.1103/PhysRevLett.129.075001]. This achievement is the culmination of more than five decades of research and gives proof that laboratory fusion, based on fundamental physics principles, is possible. This Letter reports on the target, laser, design, and experimental advancements that led to this result.

Efficacy of Acupuncture Combined with Traditional Chinese Medicine Fumigation Therapy in Sequelae of Pelvic Inflammatory Disease: A Systematic Review and Meta-Analysis

BACKGROUND AND OBJECTIVE

Acupuncture combined with traditional Chinese medicine fumigation is increasingly being used in treating sequelae of pelvic inflammatory disease (SPID). However, there is a lack of meta-analysis on the effectiveness of acupuncture combined with traditional Chinese medicine fumigation in treating SPID. The aim of this study was to assess the feasibility of combining acupuncture with traditional Chinese medicine fumigation in the treatment of SPID.

METHODS

We searched eight databases for studies on acupuncture combined with traditional Chinese medicine fumigation for the treatment of SPID from the date of establishment to October 29, 2022. We assessed the quality of included studies by using the Cochrane bias risk tool. Pooled results were expressed as risk ratios (RRs), with a 95% confidence interval (CI). In addition, we identified sources of heterogeneity by sensitivity analysis, assessed publication bias by Egger's test, and assessed the quality of the evidence by Grades of Recommendation, Assessment, Development, and Evaluation (GRADE). All statistical analyses were performed by Review Manager 5.3 and Stata 14.

RESULTS

Finally, seven studies with a total of 663 participants were included. We found a significant difference in the total effective rate in the acupuncture combined with the fumigation group compared with the acupuncture group in the treatment of SPID (RR = 1.17, 95% CI [1.09, 1.25], p = 0.0001 < 0.05; I2 = 0%; 6 trials), and a significant difference in the total effective rate in the acupuncture combined with fumigation group compared with the fumigation group in the treatment of SPID (RR = 1.42, 95% CI [1.21, 1.66], p = 0.0001 < 0.05; 5 trials).

CONCLUSION

The clinical efficacy of acupuncture combined with herbal fumigation in the treatment of SPID is relatively good. Larger scale studies are needed in the future.

Hintergrund und Ziel

Akupunktur in Kombination mit Fumigation, einem Verfahren der Traditionellen Chinesischen Medizin, wird zunehmend in der Behandlung von Folgeerscheinungen von Beckenentzündungen (SPID; sequelae of pelvic inflammatory disease) eingesetzt. Es mangelt jedoch an Metaanalysen zur Wirksamkeit der Akupunktur in Kombination mit Fumigation gemäß der Traditionellen Chinesischen Medizin in der Behandlung von SPID. Das Ziel dieser Studie ist die Beurteilung der Machbarkeit der Kombination aus Akupunktur und Fumigation gemäß der Traditionellen Chinesischen Medizin in der Behandlung von SPID.

Methoden

Wir durchsuchten acht Datenbanken nach Studien zur Akupunktur in Kombination mit Fumigation gemäß der Traditionellen Chinesischen Medizin in der Behandlung von Folgeerscheinungen von SPID von der Einrichtung bis zum 29. Oktober 2022. Wir beurteilten die Qualität der eingeschlossenen Studien mit dem Cochrane-Tool zur Bewertung des Bias-Risikos. Die gepoolten Ergebnisse wurden als Risikoquotient (RR; risk ratio) mit 95%-Konfidenzintervall (KI) ausgedrückt. Zusätzlich identifizierten wir Quellen für Heterogenität mittels Sensitivitätsanalyse, beurteilten den Publikations-Bias mittels Egger-Test und bewerteten die Qualität der Evidenz nach Grad der Empfehlungsstärke, Beurteilung, Entwicklung und Evaluierung (GRADE). Alle statistischen Analysen erfolgten mit Review Manager 5.3 und Stata 14.

Ergebnisse

Im Endeffekt wurden 7 Studien mit insgesamt 663 Teilnehmern eingeschlossen. Wir fanden einen signifikanten Unterschied in der Gesamt-Effektivitätsrate bei der Gruppe, die zur Behandlung von SPID Akupunktur in Kombination mit Fumigation erhielt, im Vergleich zur reinen Akupunkturgruppe (RR = 1,17; 95%-KI [1,09; 1,25]; p = 0,0001 < 0,05; I2-Wert = 0%; 6 Studien), und einen signifikanten Unterschied in der Gesamt-Effektivitätsrate bei der Gruppe, die zur Behandlung von SPID Akupunktur in Kombination mit Fumigation erhielt, im Vergleich zur reinen Fumigationsgruppe (RR = 1,42; 95%-KI [1,21; 1,66]; p = 0,0001 < 0,05; 5 Studien).

Schlussfolgerung

Die klinische Wirksamkeit der Akupunktur in Kombination mit Kräuter-Fumigation zur Behandlung von SPID ist relativ gut. Zukünftig sind größere Studien erforderlich.

Improved Measurement of CP Violation Parameters in B_{s}^{0}→J/ψK^{+}K^{-} Decays in the Vicinity of the ϕ(1020) Resonance

The decay-time-dependent CP asymmetry in B_{s}^{0}→J/ψ(→μ^{+}μ^{-})K^{+}K^{-} decays is measured using proton-proton collision data, corresponding to an integrated luminosity of 6  fb^{-1}, collected with the LHCb detector at a center-of-mass energy of 13 TeV. Using a sample of approximately 349 000 B_{s}^{0} signal decays with an invariant K^{+}K^{-} mass in the vicinity of the ϕ(1020) resonance, the CP-violating phase ϕ_{s} is measured, along with the difference in decay widths of the light and heavy mass eigenstates of the B_{s}^{0}-B[over ¯]_{s}^{0} system, ΔΓ_{s}, and the difference of the average B_{s}^{0} and B^{0} meson decay widths, Γ_{s}-Γ_{d}. The values obtained are ϕ_{s}=-0.039±0.022±0.006  rad, ΔΓ_{s}=0.0845±0.0044±0.0024  ps^{-1}, and Γ_{s}-Γ_{d}=-0.0056_{-0.0015}^{+0.0013}±0.0014  ps^{-1}, where the first uncertainty is statistical and the second systematic. These are the most precise single measurements to date and are consistent with expectations based on the Standard Model and with the previous LHCb analyses of this decay. These results are combined with previous independent LHCb measurements. The phase ϕ_{s} is also measured independently for each polarization state of the K^{+}K^{-} system and shows no evidence for polarization dependence.

Socio-economic factors and medical conditions affecting regular stomach cancer screening in Korea: a retrospective longitudinal study using national public health data for 11 years

OBJECTIVE

This study aimed to explore socio-economic factors and medical conditions that affect regular stomach cancer (SC) screening among Korean adults.

STUDY DESIGN

This was a retrospective observational study.

METHODS

Study subjects were 5545 adults aged ≥40 years who participated in the 2007-2012 Korean National Health and Nutrition Examination Survey and were followed up to year 2017 based on data linking to the Korean National Health Insurance Service and Korean Health Insurance Review and Assessment. Socio-economic factors included sex, age, residential area, education, occupation, marital status, disability, public and private health insurance, service through local public health organizations, history of cancer except for SC, and family history of SC. Medical factors included six gastric lesions with the possibility of facilitating SC screening, including benign gastric neoplasm, chronic atrophic gastritis, gastric polyp, Helicobacter pylori infection, intestinal metaplasia, and peptic ulcers. The outcome was adherence to SC screening, which was divided into non-adherence, irregular adherence, and regular adherence.

RESULTS

After adjusting for the effects of socio-economic factors, multivariate ordinal logistic regression revealed that participants with a history of four types of gastric lesions were more likely to regularly participate in SC screening: chronic atrophic gastritis (odds ratio [OR] 1.567; 95% confidence interval [CI] = 1.276-1.923), gastric polyps (OR 1.565; 95% CI = 1.223-2.003), H. pylori infection (OR 1.637; 95% CI = 1.338-2.003), and peptic ulcer (OR 2.226; 95% CI 1.750-2.831).

CONCLUSIONS

To improve participation in SC screening, it is necessary to implement personalized strategies for individuals at risk for gastric cancer in addition to population-based strategies for vulnerable groups.

Vegetation-fire feedbacks increase subtropical wildfire risk in scrubland and reduce it in forests

Climate dictates wildfire activity around the world. But East and Southeast Asia are an apparent exception as fire-activity variation there is unrelated to climatic variables. In subtropical China, fire activity decreased by 80% between 2003 and 2020 amid increased fire risks globally. Here, we assessed the fire regime, vegetation structure, fuel flammability and their interactions across subtropical Hubei, China. We show that tree basal area (TBA) and fuel flammability explained 60% of fire-frequency variance. Fire frequency and fuel flammability, in turn, explained 90% of TBA variance. These results reveal a novel system of scrubland-forest stabilized by vegetation-fire feedbacks. Frequent fires promote the persistence of derelict scrubland through positive vegetation-fire feedbacks; in forest, vegetation-fire feedbacks are negative and suppress fire. Thus, we attribute the decrease in wildfire activity to reforestation programs that concurrently increase forest coverage and foster negative vegetation-fire feedbacks that suppress wildfire.

[Efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation in the treatment of secondary acute myeloid leukemia]

Objective: To evaluate the efficacy and prognostic factors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with secondary acute myeloid leukemia (sAML) . Methods: In this multicenter, retrospective clinical study, adult patients aged ≥18 years who underwent allo-HSCT for sAML at four centers of the Zhejiang Hematopoietic Stem Cell Transplantation Collaborative Group from January 2014 to November 2022 were included, and the efficacy and prognostic factors of allo-HSCT were analyzed. Results: A total of 95 patients were enrolled; 66 (69.5%) had myelodysplastic syndrome-acute myeloid leukemia (MDS-AML) , 4 (4.2%) had MDS/MPN-AML, and 25 (26.3%) had therapy-related AML (tAML) . The 3-year CIR, LFS, and overall survival (OS) rates were 18.6% (95% CI 10.2%-27.0%) , 70.6% (95% CI 60.8%-80.4%) , and 73.3% (95% CI 63.9%-82.7%) , respectively. The 3-year CIRs of the M-AML group (including MDS-AML and MDS/MPN-AML) and the tAML group were 20.0% and 16.4%, respectively (P=0.430) . The 3-year LFSs were 68.3% and 75.4%, respectively (P=0.176) . The 3-year OS rates were 69.7% and 75.4%, respectively (P=0.233) . The 3-year CIRs of the groups with and without TP53 mutations were 60.0% and 13.7%, respectively (P=0.003) ; the 3-year LFSs were 20.0% and 76.5%, respectively (P=0.002) ; and the 3-year OS rates were 40.0% and 77.6%, respectively (P=0.002) . According to European LeukmiaNet 2022 (ELN2022) risk stratification, the 3-year CIRs of patients in the low-, intermediate-, and high-risk groups were 8.3%, 17.8%, and 22.6%, respectively (P=0.639) . The three-year LFSs were 91.7%, 69.5%, and 65.6%, respectively (P=0.268) . The 3-year OS rates were 91.7%, 71.4%, and 70.1%, respectively (P=0.314) . Multivariate analysis revealed that advanced disease at allo-HSCT and TP53 mutations were independent risk factors for CIR, LFS, and OS. Conclusion: There was no significant difference in the prognosis of patients who underwent allo-HSCT among the MDS-AML, MDS/MPN-AML, and tAML groups. Advanced disease at transplantation and TP53 mutations were poor prognostic factors. ELN2022 risk stratification had limited value for predicting the prognosis of patients with sAML following allo-HSCT.

Measurement of CP Violation in B^{0}→ψ(→ℓ^{+}ℓ^{-})K_{S}^{0}(→π^{+}π^{-}) Decays

A measurement of time-dependent CP violation in the decays of B^{0} and B[over ¯]^{0} mesons to the final states J/ψ(→μ^{+}μ^{-})K_{S}^{0}, ψ(2S)(→μ^{+}μ^{-})K_{S}^{0} and J/ψ(→e^{+}e^{-})K_{S}^{0} with K_{S}^{0}→π^{+}π^{-} is presented. The data correspond to an integrated luminosity of 6  fb^{-1} collected at a center-of-mass energy of sqrt[s]=13  TeV with the LHCb detector. The CP-violation parameters are measured to be S_{ψK_{S}^{0}}=0.717±0.013(stat)±0.008(syst) and C_{ψK_{S}^{0}}=0.008±0.012(stat)±0.003(syst). This measurement of S_{ψK_{S}^{0}} represents the most precise single measurement of the CKM angle β to date and is more precise than the current world average. In addition, measurements of the CP-violation parameters of the individual channels are reported and a combination with the LHCb Run 1 measurements is performed.

[Effect of ileostomy on the clinical outcomes of children with very early onset inflammatory bowel disease]

To explore the effect of ileostomy on clinical outcomes of children with very early onset inflammatory bowel disease(VEO-IBD). The clinical data of 11 children with VEO-IBD who underwent ileostomy in the Department of Gastroenterology of the Affiliated Children's Hospital of Zhengzhou University from January 2016 to December 2022 were retrospectively analyzed, and the clinical characteristics and outcomes were analyzed. A total of 11 cases were included, including 7 males and 4 females, aged 3.0 (0.9, 8.0) months. The main clinical manifestations were fever and diarrhea, with L2 type the main lesion site (according to the Paris classification of childhood Crohn's disease). There were 7 cases of gene type interleukin (IL)-10RA. After VEO-IBD ileostomy, the disease site, incidence of growth disorders, the weighted children's Crohn's disease activity index, the simplified endoscopic score of Crohn's disease, and severe mucosal inflammation activity rate were all lower than those before ileostomy (all P<0.05). The postoperative inflammatory indicators and factors were lower than those before ileostomy (all P<0.05). The mucosal barrier indicators after ileostomy were increased than before (all P<0.05). The nutritional evaluation indicators after ileostomy were improved (P<0.05). Ileostomy can reduce inflammatory response of VEO-IBD, improve intestinal mucosal barrier, reduce disease activity, and improve nutritional status.

[Effect of recombinant human thrombin for hemostasis in liver resection: a randomized controlled phase Ⅲ clinical trial]

Objective: To evaluate the hemostatic efficacy, safety and immunogenicity of recombinant human thrombin in the treatment of liver wounds that still ooze after conventional surgical hemostasis. Methods: A multicenter, stratified randomized, double-blind, placebo-controlled phase Ⅲ trial with a planned enrollment of 510 subjects at 33 centers, with a 2∶1 randomization to the thrombin group versus the placebo group. An interim analysis will be conducted after approximately 70% of the subjects have completed the observation period. The primary efficacy endpoint was the rate of hemostasis within 6 minutes at the point of bleeding that could be evaluated. Safety analysis was performed one month after surgery, and the positive rates of anti-drug antibody (ADA) and neutralizing antibody were evaluated. Results: At the interim analysis, a total of 348 subjects had been randomized and received the study drug (215 were male and 133 were female). They were aged 19-69 (52.9±10.9)years. Among them, 232 were in the thrombin group and 116 were in the placebo group, with balanced and comparable demographics and baseline characteristics between the two groups. The hemostasis rate at 6 minutes was 71.6% (95%CI:65.75%-77.36%) in the thrombin group and 44.0% (95%CI: 34.93%-53.00%) in the placebo group, respectively (P<0.001). No grade≥3 drug-related adverse events and no drug-related deaths were reported from the study.No recombinant human thrombin-induced immunologically-enhanced ADA or immunologically-induced ADA was detected after topical use in subjects. Conclusion: Recombinant human thrombin has shown significant hemostatic efficacy and good safety in controlling bleeding during liver resection surgery, while also demonstrating low immunogenicity characteristics.

Observation of New Baryons in the Ξ_{b}^{-}π^{+}π^{-} and Ξ_{b}^{0}π^{+}π^{-} Systems

The first observation and study of two new baryonic structures in the final state Ξ_{b}^{0}π^{+}π^{-} and the confirmation of the Ξ_{b}(6100)^{-} state in the Ξ_{b}^{-}π^{+}π^{-} decay mode are reported using proton-proton collision data collected by the LHCb experiment, corresponding to an integrated luminosity of 9  fb^{-1}. In addition, the properties of the known Ξ_{b}^{*0}, Ξ_{b}^{'-} and Ξ_{b}^{*-} resonances are measured with improved precision. The new decay mode of the Ξ_{b}^{0} baryon to the Ξ_{c}^{+} π^{-} π^{+} π^{-} final state is observed and exploited for the first time in these measurements.

Precision Measurement of CP Violation in the Penguin-Mediated Decay B_{s}^{0}→ϕϕ

A flavor-tagged time-dependent angular analysis of the decay B_{s}^{0}→ϕϕ is performed using pp collision data collected by the LHCb experiment at the center-of-mass energy of 13 TeV, corresponding to an integrated luminosity of 6  fb^{-1}. The CP-violating phase and direct CP-violation parameter are measured to be ϕ_{s}^{ss[over ¯]s}=-0.042±0.075±0.009  rad and |λ|=1.004±0.030±0.009, respectively, assuming the same values for all polarization states of the ϕϕ system. In these results, the first uncertainties are statistical and the second systematic. These parameters are also determined separately for each polarization state, showing no evidence for polarization dependence. The results are combined with previous LHCb measurements using pp collisions at center-of-mass energies of 7 and 8 TeV, yielding ϕ_{s}^{ss[over ¯]s}=-0.074±0.069  rad and |λ|=1.009±0.030. This is the most precise study of time-dependent CP violation in a penguin-dominated B meson decay. The results are consistent with CP symmetry and with the standard model predictions.

[Research progress on the mechanism of action of mitophagy in the occurrence and development of liver cancer]

Mitophagy, as an important link in maintaining mitochondrial homeostasis and environmental homeostasis in the liver, can remove damaged mitochondria and provide energy through autophagy and other processes. Additionally, it plays a dual role in the occurrence and development of liver cancer and can affect the therapeutic effect of liver cancer through a variety of signaling pathways. This article reviews the relationship between mitophagy and hepatitis B virus infection, liver cancer occurrence and development, liver cancer stem cells, mitochondrial division and fusion, therapeutic resistance and invasiveness of liver cancer, and other aspects.

Measurement of the Λ_{b}^{0}→Λ(1520)μ^{+}μ^{-} Differential Branching Fraction

The branching fraction of the rare decay Λ_{b}^{0}→Λ(1520)μ^{+}μ^{-} is measured for the first time, in the squared dimuon mass intervals q^{2}, excluding the J/ψ and ψ(2S) regions. The data sample analyzed was collected by the LHCb experiment at center-of-mass energies of 7, 8, and 13 TeV, corresponding to a total integrated luminosity of 9  fb^{-1}. The result in the highest q^{2} interval, q^{2}>15.0  GeV^{2}/c^{4}, where theoretical predictions have the smallest model dependence, agrees with the predictions.

Molecular Imaging of Radiation-Induced Lung Injury Using [18F]AlF Labeled Polypeptide Targeting C-X-C-Chemokine-Receptor-Type-4

PURPOSE/OBJECTIVE(S)

Radiation-induced lung injury (RILI) is a severe side effect of radiotherapy (RT) for thoracic malignancies and we currently lack established means for the early detection of RILI. In this study, we synthesized a new tracer, [18F]AlF-NOTA-QHY-04, targeting C-X-C-chemokine-receptor-type-4 (CXCR4) and investigated the feasibility of using this tracer in positron emission tomography combined with computed tomography (PET/CT) for detecting RILI.

MATERIALS/METHODS

An RILI model was established using a high-dose single RT (50 Gy/Fraction) to the right lung of female Wistar rats. Experimental animals were scanned with [18F]AlF-NOTA-QHY-04 PET/CT and [18F]FDG PET/CT at various time-points post-RT. MicroCT imaging was conducted weekly till 11 weeks post-RT. Dynamic, competition, autoradiography and histopathological studies were performed on day 14 post-RT. Biodistribution study was further performed on day 18 post-RT. Lung QHY-04 uptake was analyzed in twelve patients with radiation pneumonia, developed during or after thoracic RT.

RESULTS

The yield of [18F]AlF-NOTA-QHY-04 was 28.5-43.2%, and the specific activity was 27-33 GBq/μmol. Significantly increased [18F]AlF-NOTA-QHY-04 uptake in the damaged lung compared with that in the normal lung was observed in the experimental animal model on 6 post-RT and peaked on day 14 post-RT (0.96 ± 0.06 vs. 0.50 ± 0.05 %ID/mL, P<0.05), whereas no apparent uptake of [18F]FDG was shown on day 7 and 15 post-RT. Significant intense [18F]AlF-NOTA-QHY-04 uptake was confirmed by autoradiography. No significant difference in CT density was observed between the damaged and normal lung tissues until six weeks post-RT. Immunofluorescence staining demonstrated expression of CXCR4 was significantly increased in the damaged lung tissue, which correlated with results obtained from hematoxylin-eosin and Masson's trichrome staining. Maximum standardized uptake values (SUVmax) were significantly higher in the irradiated lung compared with that in the normal lung in 12 patients with radiation pneumonia (3.07 ± 0.86 vs. 0.585 ± 0.17, P<0.001). SUVmax of patients with grade 2 RILI was significantly higher than that of patients with grade 1 RILI (3.30 ± 0.65 vs. 1.64 ± 0.08, P<0.05).

CONCLUSION

This study indicated that [18F]AlF-NOTA-QHY-04 PET/CT imaging can detect RILI noninvasively and earlier than [18F]FDG PET/CT in a rat model. Clinical studies verified its' feasibility, suggesting the clinical potential of [18F]AlF-NOTA-QHY-04 as a PET/CT tracer for early monitoring of RILI.

Overcoming Radio-Immunotherapy Treatment Resistance through ILT4 Blockade and Reversal of HFRT Induced CXCL1-CXCR2 Axis Activation and Tumor-Associated Macrophage Immunosuppression

PURPOSE/OBJECTIVE(S)

Immunotherapy combined with radiotherapy (iRT) has unlimited potential, but up to 60% of cancer patients do not benefit from it. Enhancing the anti-tumor immune stimulatory effect triggered by radiotherapy is the key to overcome iRT resistance. Immunoglobulin-like transcript (ILT) 4 is a potential immune checkpoint molecule, highly expressed in various tumor cells, but its role in radiotherapy is still unknown. This study confirmed the role and molecular mechanism of ILT4 in suppressing radiotherapy immunosuppressive microenvironment formation and promoting tumor radiotherapy resistance. We propose a new therapeutic strategy that block ILT4 to enhance the efficacy of radiotherapy, and cooperate with radiotherapy to reverse immunotherapy resistance.

MATERIALS/METHODS

Using multiplex immunohistochemistry, we analyzed ILT4 expression, tumor-associated macrophage (TAM) /T cell phenotype and quantity in tumor patient treated with SBRT. Using mice subcutaneous tumor models, Single-cell RNA sequencing and multiplex flowcytometry, we assessed the role of ILT4 inhibition and hyper-fractionated radiotherapy (HFRT) on preventing tumor growth and immune escape. The molecular signaling and cytokines regulated by ILT4 under HFRT were analyzed by transcriptome sequencing and further verified by molecular experiments. By establishing cancer cell/TAM co-culture system in vitro, using CXCL1 protein or CXCR2 inhibitor and macrophage/CD8+ T cell deletion antibody in vivo, we identified the downstream pathway and cytokine of ILT4 to enhancing HFRT -induced TAM immune response.

RESULTS

In the tumor specimens of NSCLC patients treated with SBRT, we found that high ILT4 expression predicted poor progression-free survival and more M2-TAM recruitment. Among the C57BL/6 mice model, ILT4 inhibition in cancer cells reduced HFRT mediated M2-TAMs accumulation, and to sustain activation and proliferation of CD8+ T cells, and eventually suppressed tumor progression. Mechanistically, RT promoted ILT4 expression, which subsequently induced NF-κB pathway activation and CXCL1 secretion to enhance M2-TAMs migration in vitro. Using CXCL1 protein or CXCR2 inhibitor administration, inferring that ILT4 promotes TAMs migration via NF-κB-CXCL1-CXCR2 axis. Consistently, depletion of TAMs blocked the T cell function impairment and radiotherapy resistance induced by ILT4 in vivo. Importantly, targeting ILT4 potentiated the effect of radiotherapy, overcomes radio-immunotherapy treatment resistance.

CONCLUSION

ILT4 mediates HFRT-induced M2-like TAMs recruitment and subsequently T cell response impairment by regulating NF-κB-CXCL1-CXCR2 axis. ILT4 is an attractive drug target for enhancing radiotherapy and overcomes radio-immunotherapy treatment resistance.

Metformin Antagonizes Radiotherapy-Induced Anti-Tumor Effects via Inhibition of cGAS-STING Pathway Mediated Immune Responses

PURPOSE/OBJECTIVE(S)

Radiotherapy induced anti-tumor effects depend on both direct tumor cell death caused by radiation and immune activation mediated by cGAS-STING pathway. Metformin (MTF), which could augment the tumoricidal efficiency of radiation, is indicated to be a radiosensitizer by basic research. However, several large prospective clinical trials proved otherwise. In present study, we intend to interrogate the effects of MTF on radiotherapy-induced anti-tumor immune responses and try to explain the inconsistent outcomings of radiotherapy combined with MTF in basic research and clinical practice.

MATERIALS/METHODS

To explore the effects of MTF on radiotherapy induced anti-tumor effects, tumor models were established using E0771, B16F10 and LLC cell lines in both immunocompetent and immunodeficient mice. To investigate the composition and function of immune cells in tumor microenvironments, single-cell transcriptome sequencing of CD45+ cells sorted from tumor microenvironments were carried out, and flow cytometry and multiple immunofluorescence analysis were then performed for validation. To reveal the possible mechanisms, tumor cells were subjected to radiotherapy in the presence or absence of MTF in vitro, and RNA-sequencing was then employed followed by subsequent validation with western blotting, real-time qPCR and flow cytometry.

RESULTS

We found that systematic administration of MTF could significantly inhibit radiotherapy-induced anti-tumor effects in immunocompetent mouse models. Single cell sequencing of CD45+ cells sorted from tumor microenvironments and further validation showed that administration of MTF dramatically attenuated the infiltration and cytotoxic capacity of CD8+ T cells after radiotherapy. cGAS-STING pathway in tumor cells was required for maximum efficiency of radiotherapy, while MTF curbed cGAS-STING pathway after radiotherapy in a dose-dependent pattern by enhancing autophagy and reducing cytoplasmic mitochondrial DNA accumulation, which contributed to compromised anti-tumor effects.

CONCLUSION

Our findings indicated that MTF could antagonize radiotherapy-mediated anti-tumor effects by inhibiting the activation of cGAS-STING pathway and subsequent immune responses, which may partially explain the unsatisfied outcomes of radiotherapy combined with MTF in clinical practices. Since the anti-tumor effects of radiotherapy rely not only on the tumor-killing efficiency of radiation but also on systematic immune responses, our findings suggest that cautions are needed when MTF is administrated with radiotherapy in clinical practice.

Targeting XPO1 Combined with Radiotherapy to Enhance Systemic Anti-tumor Effects in Non-Small Cell Lung Cancer

PURPOSE/OBJECTIVE(S)

The combination of radiation and radiosensitizing chemotherapeutic agents have shown promising anti-tumor effects in NSCLC. Acting as an oncogenic driver, XPO1 is frequently overexpressed and/or mutated in lung cancer. Thus, suppression of XPO1-mediated nuclear export presents a unique therapeutic strategy. We hypothesize that XPO1 inhibition combined with radiotherapy (XRT) may remodel the tumor immune microenvironment (TIME) and reduce radioresistance, thus enhance systemic anti-tumor effects.

MATERIALS/METHODS

Herein, we optimized a small molecule inhibitor, WJ01024, which can bind to XPO1 and antagonize its activity to inhibit nuclear export. In the C57BL/6 mouse subcutaneous tumor model, we evaluated the ability of different treatment regimens containing oral WJ01014 single or combined with XRT (one fractions of 15 Gy) in tumor control and tumor recurrence inhibition. The effects of each treatment regimen on the alterations of immunophenotypes, including the quantification, activation, proliferative capacity, exhaustion marker expression, and memory status, were evaluated by flow cytometry.

RESULTS

In our study, we found that the overexpression of XPO1 was associated with poor prognosis and survival in radioresistant patients with NSCLC. The combination therapy of WJ01024 and XRT resulted in an increase of apoptosis and a decrease of proliferation compared to monotherapy, which was closely correlated with tumor regression and improved survival in the C57BL/6 mouse subcutaneous tumor model. Notably, we found that WJ01024 were shown to enhance the therapeutic effect of XRT by remodeling TIME. Compared with XRT, the addition of WJ01024 increased the infiltration and proliferation of radiation-stimulated CD8+ T cells, which especially promoted the production of interferon-γ and granzyme B. Moreover, the combination therapy also reversed the immunosuppressive effect of radiation on the percentage of Tregs and exhausted T cells in mouse xenografts. Thus, the TIME was significantly improved in combination therapy. Strikingly, mechanistic studies suggested that the activation of cyclic GMP-AMP synthase/stimulator of interferon genes (cGAS/STING) signaling pathway is required to reshape TIME and produce synergistic anti-tumor effect with the combination of WJ01024 and XRT.

CONCLUSION

Our findings suggest that WJ01024 might be a potential synergistic treatment for radiotherapy to control the proliferation of NSCLC cells, promote tumor regression and prolong survival in mouse model of NSCLC by activating cGAS/STING signaling, and this in turn potentiate the immune microenvironment.

Dissecting Systemic T Cell Responses after Stereotactic Ablative Radiotherapy in NSCLC by Single-Cell RNA and T Cell Receptor Sequencing

PURPOSE/OBJECTIVE(S)

There is accumulating evidence that stereotactic ablative radiotherapy (SABR) modulates immune responses to cancer; combining SABR and immunotherapy could promote the abscopal effect, but the precise effects of SABR on patients' systemic T cells is unclear. Here, we investigated SABR-induced systemic T cell response in early-stage non-small cell lung cancer (NSCLC) by single-cell RNA and T cell receptor sequencing.

MATERIALS/METHODS

We performed single-cell RNA and T cell receptor sequencing on 29,439 T cells from four pairs of peripheral blood before and after SABR in early-stage NSCLC patients. Cell clustering and dimensionality reduction, SingleR, feature genes score, and TCR profiling analyses were used to investigate the heterogeneity of T cells and their changes following SABR.

RESULTS

We identified fourteen T cell subtypes using unsupervised graph-based clustering of uniform manifold approximation and projection. By comparing the gene set scores of CD8_TE and CD8_EM pre- and post-SABR, we found both cytotoxic and inhibitory scores were significantly elevated in CD8_TE (both P < 0.001), while cytotoxic score was significantly increased in CD8_EM (P < 0.001) after SABR. We also found that CD4_TE showed increased cytotoxic scores and decreased Treg scores (P < 0.001 and < 0.05, respectively), while Treg cells showed decreased inhibitory and Treg scores (P < 0.001 and <0.01, respectively) after SABR. The proportion of large TCR clones was higher after SABR, which was accompanied by a decrease in proportion of single clones. When we compared the transcriptomes of CD8_TE cells between the single, small and large clones post-SABR, we found high expression of GZMB and KLRC3 in cells with large clones, and GZMK, IL7R, and SELL in small and single clones. This suggested that T cells after SABR with large clones may have higher cytotoxicity than those with small and single clones.

CONCLUSION

Our study identified systemic T cell activation after SABR at single-cell resolution, providing unprecedented insight into the immune-modulatory role of SABR in early-stage NSCLC.

Single-Cell RNA Sequencing Reveals a Subset of cMAS can Aggravate RIHD through CXCL1-CXCR2 Axis

PURPOSE/OBJECTIVE(S)

Radiation induced heart disease (RIHD) is any form of cardiac toxicity induced by radiation therapy (RT) for thoracic cancers. Our previous studies have shown that RT obviously contributed to cardiovascular diseases-specific death over 3 years while RT became protective in the short term within 2 years survival in non-small cell lung cancer patients. Here, single cell RNA sequencing (scRNA-seq) was performed to identify various cell subsets and investigate their functions and dynamics in RIHD which offered several targets for early clinical interventions to alleviate RIHD.

MATERIALS/METHODS

Based on evaluation of histopathological characteristics, ejection fraction and serum levels of cardiac injury biomarkers, we have established mouse models during different stages to simulate clinical RIHD progression. Hence, we performed single cell RNA-sequencing of RIHD models to characterize the diversity within specific cell types and obtain basic information of differently expressed genes (DEGs). We investigated the role of several cell clusters and DEGs in RIHD through bioinformatics analysis and experimental verification. In vivo, mouse models were given intraperitoneal injection of CXCR2 inhibitor. Bone marrow macrophages and primary cardiac fibroblasts were extracted for in vitro experiments.

RESULTS

RIHD processes were divided into acute injury, compensation and decompensation stage. Transcriptomes of 31769 single cells from cardiac suspension have been profiled. Analysis of scRNA-seq revealed that there were 30 cell clusters participating in RIHD. The fraction of cell populations varied greatly at three stages which indicated RIHD was a dynamic process and each cell cluster functioned differently at different stages. Notably, we observed cardiac resident macrophages (cMAS) subset accounted for the highest fraction during the compensatory period and decreased in decompensation period. Pseudotime analysis showed cMAS had a different developmental trajectory compared to myeloid derived cells. Moreover, CXCR2 was significantly expressed in cMAS cluster. Ligand-receptor interaction results suggested that CXCL1 secreted by cardiac fibroblasts bind primarily to CXCR2+ cMAS and participated in the formation of the extracellular matrix (ECM) related to cardiac fibrosis. Moreover, cardiac fibrosis of RIHD models were relieved after CXCR2 inhibitor treatment. CXCL1 expression in primary cardiac fibroblast elevated after RT.

CONCLUSION

The identification of main cell clusters provided a new insight to investigate RIHD through dynamics of cell phenotypes and cell-cell communications during RIHD processes. In compensation stage, CXCR2+ cMAS could be activated by CXCL1 secreted by cardiac fibroblasts. Both were associated with ECM and contribute to the decompensation stage.

IL-1β+ Tumor Associated Macrophages Induced by Type I Interferon Initiates Radiotherapy-Mediated Abscopal Effect

PURPOSE/OBJECTIVE(S)

Both experimental and clinical studies have proved that radiotherapy can lead to not only local control of irradiated tumors, but also tumor regression of non-irradiated area, termed as abscopal effect. Abscopal effect has been attributed to radiotherapy-induced innate and adaptive anti-tumor immune responses. However, the detailed molecular mechanisms and key cellular components are still unclear. So, the purpose of this study is to reveal the key molecular mechanisms and essential cells in inducing abscopal effect.

MATERIALS/METHODS

Bilateral MC38 subcutaneous tumor mouse models were established, and primary tumors were subjected to one fraction of 15Gy. CD45+ cells were sorted from both primary and abscopal tumors 3-, 7-, 17- and 24-day post radiotherapy respectively and subjected to single-cell RNA sequencing followed by standard bioinformatic analysis with R studio. To verify the findings, flow cytometry, mIHC and real-time qPCR were carried out to analyze the cellular and molecular components in tumor microenvironments. Cellular depletion experiments and conditional knockout mice were finally employed to confirm key mechanisms that contribute to abscopal effect.

RESULTS

The primary and abscopal immune microenvironments showed different repertoires time-dependently. Radiotherapy induced durable type I interferon (IFN-I) responses with dramatic infiltration and activation of CD8+ T cells and tumor associated macrophages (TAMs) in primary tumors. However, in abscopal tumors, we found that TAMs rather than CD8+ T cells were the predominant population activated in early stages (3- and 7-day post radiotherapy), and functional CD8+ T cells enriched until late stages (24-day post radiotherapy). Thorough analysis of scRNA-seq and experimental validation discovered a unique subset of TAMs characterized by high expression of IL-1β emerged as early as 3-day post radiotherapy in both primary and secondary tumor immune microenvironments, termed as IL-1β+ TAMs herein. IL-1β+ TAMs were the main activated component in abscopal tumors in early stage, and strongest respondent to IFN-I pathway. Abscopal effect was significantly attenuated when IFN-I response was abolished in either primary or abscopal tumors or TAMs were depleted from abscopal tumors.

CONCLUSION

Our data identified a subset of immune cells, IL-1β+ TAMs, and IFN-I as the essential cellular and molecular components that contribute to abscopal effect. Mechanically, radiotherapy-induced dramatical IFN-I response in primary tumors lead to enrichment of IL-1β+ TAMs, which initiated the anti-tumor immune response in abscopal tumors. All these findings provided theoretical basis for understanding and improving radiotherapy-induced abscopal effect.

Spatial Proteome Analysis Identifies Lymphocyte CD44 as a Biomarker Associated with SBRT Resistance in Early-Stage Non-Small Cell Lung Cancer

PURPOSE/OBJECTIVE(S)

To discover and validate spatially-resolved protein markers associated with resistance to SBRT in early-stage NSCLC patients.

MATERIALS/METHODS

We initially evaluated a discovery cohort of 44 early-stage NSCLC patients treated with SBRT as first-line treatment at the Shandong cancer hospital. Using the GeoMx DSP system, 71 proteins were measured in five molecular compartments (tumor, leukocyte, lymphocyte, macrophage, and stroma) on pre-treatment samples. Candidate biomarkers were orthogonally validated with the Gem AQUA method of quantitative immunofluorescence (QIF). For internal independent cohort validation, we assessed pre-treatment samples derived from 150 NSCLC patients who receive radiotherapy. We further analyzed 100 radiotherapy untreated patients with operable NSCLC to address prognostic significance.

RESULTS

Using continuous log-scaled data, we identified CD44 expression in the lymphocyte compartment (CD3+) as a novel predictor of poor progression-free survival (PFS) (multivariate HR = 7.323, p = 0.0079) and overall survival (OS) (multivariate HR = 8.65, p = 0.028) in the discovery set. High CD44 expression in the tumor compartment (pan-cytokeratin, CK+) predicted significantly shorter OS (multivariate HR = 2.208, p = 0.0212), with no significant difference in PFS. We validated by QIF that lymphocyte CD44 levels were associated with resistance to SBRT therapy and prognostic for poor outcomes. Using QIF in an independent radiotherapy treated cohort, we validated that CD44 levels in the lymphocyte compartment were associated with poor PFS and OS. High lymphocyte cell CD44 was not prognostic in non-radiotherapy-treated cohort. Using DSP data, intratumoral regions with elevated lymphocyte cell CD44 expression showed prominent upregulation of CD127, ARG1 and VISTA in the discovery Cohort.

CONCLUSION

In conclusion, we identified and validated lymphocyte cell CD44 as a biomarker indicative of resistance to SBRT or radiotherapy in patients with NSCLC. Further evaluation is warranted to address the predictive value of lymphocyte cell CD44 in multi-institutional studies and clinical trials.

Irradiated Tumor Cells-Derived Exosomes Modulate Macrophage Polarization by Targeting SHP-2 Mediated Metabolic Reprogramming

PURPOSE/OBJECTIVE(S)

Tumor-associated macrophages (TAMs) constitute a plastic and heterogeneous cell population of the tumor microenvironment (TME) that can regulate tumor proliferation and support resistance to therapy, constituting promising targets for the development of novel anticancer agents. The efficacy of radiotherapy, a mainstay of cancer treatment, can strongly influence TAMs recruitment and phenotype. Our previous results demonstrated that SHP-2 and PD-L1 inhibition combined with radiotherapy enhances systemic antitumor effects in non-small cell lung cancer (NSCLC). Especially, SHP-2 has an important effect on the polarization of TAM in the context of radiotherapy. However, the immune mechanisms of SHP-2 in TAM remain largely unknown, and this leads us to implement this project.

MATERIALS/METHODS

Transmission electron microscopy and differential ultracentrifugation were used to verify the existence of exosomes. The bone marrow-derived macrophages (BMDM) and peritoneal macrophages (PM) were derived from C57BL/6 mice for vitro tests. In vivo and in vitro assays were used to identify roles of exosomal miRNA targeting SHP-2. To investigate the regulating function of SHP-2 in TAMs, co-culture experiments, qPCR, Western Blot, Flow Cytometry and Oxygraph-2k were employed. And we also explore tumor growth and tumor environment changes in SHP-2 flox/floxLyz-Cre+/- (CKO) mice.

RESULTS

We found that irradiated tumor cells-derived exosomes reprogramed their energy metabolism and polarized primary macrophages to an anti-inflammatory phenotype. Furthermore, SHP-2 in macrophages was a direct target of exosomal miR-138-5p from irradiated tumor cells. In vitro study also demonstrates that miR-138-5p can down-regulate SHP-2 in the BMDMs and PMs. Further research has shown that SHP-2 negatively regulated glycolysis through dephosphorylating Pyruvate kinase M2 (PKM2) at the Tyr105 site. In addition, SHP-2 can inhabit PKM2 translocation to the nucleus by dephosphorylating PKM2 at the Ser37 site. Thus, the SHP099 (a SHP-2 inhibitor) can uptake and utilization of glucose by SHP-2/PKM2(Tyr105) (Ser37)/β-catenin/LDHA/Glut-1 axis, suggesting that SHP099 plays positive roles on glycolysis and M1-polarized. In vivo study showed that SHP-2 flox/floxLyz-Cre+/- (CKO) mice display enhanced control of solid tumor growth, accompanied by increased the proportion of M1-like macrophages.

CONCLUSION

Our study demonstrates that exosomal miR-138-5p from irradiated tumor cells can modulate macrophage polarization by targeting SHP-2. And SHP-2 negatively regulates glycolysis and polarize macrophage to an M2 phenotype by SHP-2/PKM2(Tyr105) (Ser37)/β-catenin/LDHA/Glut-1 axis.

High Dose Hyperfractionated Thoracic Radiotherapy vs. Standard Dose for Limited Stage Small-Cell Lung Cancer: A Multicenter, Open-Label Randomized, Phase 3 Trial

PURPOSE/OBJECTIVE(S)

Limited stage small-cell lung cancer (LS-SCLC) is associated with poor prognosis. We aimed to assess the efficacy and safety of high-dose, hyperfractionated thoracic radiotherapy of 54 Gy in 30 fractions compared with standard dose (45 Gy in 30 fractions) as a first-line treatment for LS-SCLC.

MATERIALS/METHODS

The study was an open-label, randomized, phase 3 trial, done at 16 public hospitals in China. Key inclusion criteria were patients aged 18-70 years, with previously histologically or cytologically confirmed LS-SCLC, previously untreated or received 1-2 courses of intravenous cisplatin (75 mg/m²of body-surface area, on day 1 or divided into two days of each cycle) or carboplatin (area under the curve of 5 mg/mL per min, day 1 of each cycle)and intravenous etoposide (100 mg/m²of body-surface area, on days 1-3 of each cycle), and an Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.Eligible patients were randomly assigned (1:1) to receive volumetric-modulated arc radiotherapy (VMAT) of 45 Gy in 30 fractions or the simultaneous integrated boost VMAT (SIB-VMAT) of 54 Gy in 30 fractions to the primary lung tumor and lymph node metastases starting 0-42 days after the first chemotherapy course. Both groups of patients received thoracic radiotherapy twice per day and 10 fractions per week. Prophylactic cranial radiation (PCI, 25 Gy in 10 fractions) was implemented to patients with responsive disease. The primary endpoint was overall survival. Safety was analyzed in the as-treated population.

RESULTS

Between June 30, 2017, and April 6, 2021, 224 eligible patients were enrolled and randomly assigned to 54 Gy (n = 108) or 45 Gy (n = 116). Median follow-up for the primary analysis was 45 months (IQR 41-48). Median overall survival was significantly improved in the 54 Gy group (62.4 months) compared with the 45 Gy group (43.1 months; p = 0.001). Median progression-free survival was significantly improved in the 54 Gy group (30.5 months) compared with the 45 Gy group (16.7 months; p = 0.044). The most common grade 3-4 adverse events were neutropenia (30 [28%] of 108 patients in the 54 Gy group vs 27 [23%] of 116 patients in the 45 Gy group), neutropenic infections (6 [6%] vs 2 [2%]), thrombocytopenia (13 [12%] vs 12 [10%]), anemia (6 [6%] vs 4 [3%]), and esophagitis (1 [1%] vs 3 [3%]). Treatment-related serious adverse events occurred in 9 [8%] patients in the 54 Gy group and 16 [14%] patients in the 45 Gy group. There were one treatment-related deaths in 54 Gy group (myocardial infarction).

CONCLUSION

Compared with standard thoracic radiotherapy dose of 45 Gy, the high dose of 54 Gy improved overall survival and progression-free survival without increasing toxicities in patients with LS-SCLC, supporting twice-daily hyperfractionated thoracic radiotherapy of 54 Gy with concurrent chemotherapy is an alternative treatment option for LS-SCLC. This study is complete and registered with ClinicalTrials.gov, NCT03214003.

TFAM Modulates Cardiomyocytes Pyroptosis Induced by Ionizing Radiation through mtDNA/TLR9/NF-kB Pathway

PURPOSE/OBJECTIVE(S)

Mitochondrial transcription factor A (TFAM) is a pivotal factor for regulating mitochondrial DNA (mtDNA) replication, transcription and biogenesis. Previous studies have reported that cytosolic mtDNA stress can lead to cardiomyocytes pyroptosis, which is characterized by inflammasome formation. In this study, we attempted to investigate the mechanism of TFAM regulate cardiomyocytes pyroptosis induced by ionizing radiation.

MATERIALS/METHODS

The peripheral blood serum of patients with esophageal cancer before and after definitive chemoradiotherapy was collected for Luminex multiplex cytokine assays. C57BL/6 mice were irradiated with the whole heart using small animal radiation research platform (SARRP) to construct a radiation-induced myocardial damage (RIMD) mouse model, and the ventricular function was evaluated using 9.4T Bruker magnetic resonance (MR) scanner. The function changes of cardiomyocytes exposed to radiation were observed in vitro and in vivo after knocking out GSDMD. Furthermore, the changes of mitochondrial function, the levels of cytosolic mtDNA, and the protein levels of NF-kB and pyroptosis pathway in irradiated cardiomyocytes were analyzed by knockdown and overexpression of TFAM in vitro and in vivo.

RESULTS

By multifactor cytokine assays we found that pyroptosis related IL-1β and IL-18 were significantly increased in patients with high mean heart dose (MHD) after radiotherapy, while those with low MHD were not significantly increased after radiotherapy. Next, we successfully constructed the RIMD mouse model using a single heart irradiation of 20 Gy. We found that the gene expression of pyroptosis pathway was significantly up-regulated after cardiac irradiation by myocardial tissue transcriptomic sequencing. Compared with wild-type (WT) mice, cardiac systolic function of Gsdmd-/- mice was significantly improved at 1, 2, 6, 12, and 24 weeks after heart irradiation. In vitro, we also demonstrated increased viability of irradiated cardiomyocytes by knocking out GSDMD. In vitro and in vivo experiments confirmed the expression of TFAM decreased after radiation. By overexpression of TFAM, we found that irradiated cardiomyocytes showed improved mitochondrial function, decreased release of mtDNA into cytoplasm through mitochondrial permeability transition pores (mPTPs), decreased binding of cytosolic mtDNA to TLR9, and decreased expression of NF-kB and pyroptosis pathway proteins. Dual luciferase gene reporter assays and Chromatin immunoprecipitation (CHIP) assay confirmed that p65 could bind the NLRP3 promoter region. In addition, we found that ventricular function deteriorated and improved in mice with knockdown and overexpression of TFAM through adeno-associated virus serotype 9 (AAV9), respectively.

CONCLUSION

Our study indicated that TFAM regulate irradiated cardiomyocytes pyroptosis through mtDNA/TLR9/NF-kB pathway. We provide a novel mechanism of RIMD, revealing an underappreciated intervention target for RIMD.

Carm1 Inhibition Potentiates Irradiation-Induced Antitumor Immunity via Tumor Intrinsic STING Pathway Activation

PURPOSE/OBJECTIVE(S)

Radiotherapy is commonly applied in multiple cancer types. Besides irradiation induced direct cell death, radiotherapy stimulated significant immune responses for tumor control. Intact and functional cGAS-STING pathway in both tumor cells and host cells is indispensable for efficient irradiation-induced anti-tumor effects. Coactivator-associated arginine methyltransferase 1 (Carm1) is emerging as an attractive therapeutic target and a biomarker for prognosis in various types of cancer. It has been reported that Carm1 inhibition could improve immunotherapy induced anti-tumor effects. However, it remains unclear how tumor cell intrinsic Carm1 affects irradiation-induced anti-tumor immunity.

MATERIALS/METHODS

Carm1 deficient cell lines were established in MC38 and B16F10 murine cancer cells using the CRISPR/Cas9 technology. To verify the effects of tumor `subcutaneous tumor mouse models were established and one fraction of 15Gy was administrated when the tumor volume reached 200mm3, followed by flow cytometry assays. Transcriptome sequencing, protein mass spectrometry, single-cell sequencing, Digital Spatial Profiling (DSP), real-time qPCR, western blotting, immunofluorescence and co-immunoprecipitation were carried out to explore and verify possible molecular mechanisms.

RESULTS

Here we found Carm1 deficiency in tumor cells dramatically enhanced irradiation-induced anti-tumor immune responses. Transcriptome sequencing of irradiated tumor cells and further experiments then validated that cGAS-STING pathway was significantly activated after irradiation in the absence of Carm1 in tumor cells, which contributed to enhance anti-tumor immunity after irradiation. Mechanistically, Carm1 deficiency in tumor cells attenuated autophagy, resulting in increased cytoplasmic mtDNA enrichment and enhanced cGAS-STING pathway activation. On the other hand, we also found that Carm1 caused asymmetric arginine methylation (ADMA) modification of TBK1 with reduced phosphorylation level, and Carm1 deficiency could activate cGAS-STING pathway by reducing AMDA modification and enhancing phosphorylation of TBK1. Finally, Carm1 inhibitor EZM2302 was applied in combination with radiotherapy in vitro, and it's indicated that combination therapy resulted in intensive anti-tumor immunity and prominent abscopal effects.

CONCLUSION

In this study, we identified that Carm1 ablation in tumor cells could promote irradiation-induced antitumor immunity through tumor cell intrinsic STING pathway activation. Mechanically, Carm1 deficiency directly activated the cGAS-STING pathway by interacting with TBK1 and increased mtDNA accumulation in cytoplasm by inhibiting autophagy. These findings provided new strategies for targeting Carm1 to boost the efficacy of radiotherapy.

RUNX1 as a Potential Target for Combined Radioimmunotherapy of Lung Adenocarcinoma

PURPOSE/OBJECTIVE(S)

Radioimmunotherapy for non-small cell lung cancer has good clinical application prospects. The role and mechanism of RUNX1 in DNA damage repair were explored for its potential role in lung adenocarcinoma radioimmunotherapy.

MATERIALS/METHODS

To study the effect of RUNX1 expression level on the expression of DNA damage repair system related factors and radiation sensitivity of lung adenocarcinoma cells. As an important nuclear transcription factor, RUNX1 was explored whether directly regulating the expression of Nrf2, Rad51, BRCA1, and verifying their respective DNA binding sites in the promoter region through relevant databases. To observe the effect of RUNX1 knockout and overexpression on the expression level of PD-L1 in tumor cells at the cell level; The effect of RUNX1 expression level on the sorting and presentation of PD-L1 cells was investigated by the method of nucleocytoplasmic separation. According to literature reports, CMTM6 and ALIX play a key role in the process of PD-L1 cell sorting and presentation, and explore whether RUNX1 plays a role through this factor. The effect of phosphorylation level of different splicing bodies of RUNX1 (RUNX1a/b/c) on the expression level and DNA damage repair system related factors on tumor radiosensitivity were also explored.

RESULTS

According to TCGA database, RUNX1 is highly expressed and phosphorylated in lung adenocarcinoma. Through gene comparison with the database, it was found that RUNX1 binding sites existed in the promoter region of several factors related to this study, including ALIX, Nrf2, BRCA1, RAD51, ATM, H2AX, etc. After being activated by MAPKp38 phosphorylation, RUNX1a can positively regulate Nrf2 signal pathway. The expression of RUNX1 and p-RUNX1 is time-dependent on ionizing radiation. At the same time, it was found that the expression of RUNX1 and p-RUNX1 was dose-dependent on ionizing radiation, and the expression trend of Nrf2 signal pathway related factors was consistent with RUNX1. RUNX1 regulates the expression of PD-L1, BRCA1, ALIX and Nrf2. Bioinformatics analysis and flow cytometry data show that RUNX1 has inhibitory effect on tumor microenvironment of lung adenocarcinoma.

CONCLUSION

RUNX1 regulates DNA damage repair system and has inhibitory effect on tumor immunity. Inhibiting the expression of RUNX1 in lung adenocarcinoma cells can enhance the effect of radioimmunotherapy.

Intraoral Gavage of Second-Generation Probiotic Lactobacillus Reuteri Releasing IFN-β (LR-IFN-β) Mitigates Intestinal Irradiation Toxicity and Improves Survival During Whole Abdomen Irradiation (WAI)

PURPOSE/OBJECTIVE(S)

We sought to establish a method by which to overcome the toxicity of WAI to facilitate clinical application in Ovarian Cancer patients.

MATERIALS/METHODS

We irradiated C57BL/6J mice to 19.75 Gy WAI and assessed the primary endpoint of overall survival (OS). In a separate experiment, mice were irradiated to 12 Gy WAI and intestinal barrier integrity was compared between groups: control (0 Gy), irradiation only, 12 Gy + LR, 12 Gy + IFN-β, and 12 Gy + LR-IFN-β. Luminex assay of plasma and intestinal cells were also assayed at day 5 after WAI for radiation-induced inflammatory cytokines, and fecal matter was analyzed for LR-IFN-β clearance and levels of the LR-derived IFN-β gene from day 1 to 5 in control non-irradiated mice. Moreover, fluorescent beads were intraorally administered three hours prior to sacrifice at days 2 or 5 after WAI, and blood was assayed for beads.

RESULTS

Mice receiving LR-IFN-β (109 bacteria in 100 mL of saline) 24-hours following a single fraction of 19.75 Gy WAI showed improved OS compared to control irradiated mice (p = 0.03). LR-IFN-β gavage maintained intestinal barrier integrity (p < 0.05) by stimulating intestinal stem cells regenerations (improved levels of Lgr5+ cells, occludin, and I-CAM; p < 0.05), and reduced levels of intestinal pro-inflammatory cytokines, including IFN-γ (p = 0.0261), IL-3 (p < 0.0020) and IL-17 (p < 0.0070). There was no significant effect of control LR or intraperitoneal injection of IFN-β protein at 24 hours after WAI. Detectable levels of LR-IFN-β bacteria were also cleared from fecal matter by day three via colony assay and rt-PCR, with no detectable growth of LR-IFN-β in blood from gavaged irradiated mice (13.5 Gy WAI).

CONCLUSION

LR-IFN-β is both a feasible and effective radiation mitigator that could potentially improve the management of ovarian cancer patients. Furthermore, the subsequent addition of platinum/taxane-based chemotherapy to the combination of WAI and LR-IFN-β should reduce tumor volume while protecting the intestine and thus improve overall survival in ovarian cancer patients.

Safety and Efficacy Analysis of Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC) Treated with SHR-1316 Plus Chemotherapy and Sequential Chest Radiotherapy as First-Line Therapy from a Phase II Trial

PURPOSE/OBJECTIVE(S)

CAPSTONE-1, a phase 3 trial, showed that SHR-1316 (PD-L1 antibody) combined with standard first-line chemotherapy could prolong overall survival (OS) in patients (pts) with ES-SCLC. The CREST trial reported consolidative thoracic radiotherapy (TRT) of 30 Gy in 10 fractions provided a 10% 2-year OS benefit and more intensive TRT should be investigated in ES-SCLC. In the era of immunotherapy, the role of TRT also needs further exploration. Therefore, we designed this clinical trial to investigate the efficacy and safety of SHR-1316 plus first-line chemotherapy followed by TRT combined with SHR-1316.

MATERIALS/METHODS

Key inclusion criteria were pts aged 18-75 years, with previously untreated histologically or cytologically confirmed ES-SCLC, and an ECOG performance status of 0-1. Eligible pts would receive 4∼6 cycles of SHR-1316 (20mg/kg, D1, q3w) combined with EP/EC (etoposide, 100mg/m2, D1-5, q3w and cisplatin, 75mg/m², D1-3, q3w or carboplatin, AUC = 5, D1, q3w), followed by SHR-1316 combined with TRT (≥3 Gy*10 f or ≥2 Gy*25 f, involved-field irradiation), and then the maintenance therapy with SHR-1316 until disease progression or intolerable adverse events (AEs). The main endpoints included ORR, PFS and safety.

RESULTS

From October 2020 to January 2023, 33 pts received SHR-1316 and sequential consolidative TRT. Among them, 19 pts received high-dose TRT (>3 Gy*10 f or ≥2 Gy*25 f) and 14 pts received low-dose TRT (≤3 Gy*10 f or<2 Gy*25 f). The median age was 62 (range: 38-73). Most pts were male (28, 84.8%), former smokers (22, 66.7%) with an ECOG performance status 1 (32, 97%). Ten (30.3%) pts were diagnosed with brain metastasis and 10 (30.3%) pts had liver metastasis at baseline. At the data cutoff date, 9 pts remained on treatment, the average number of treatment cycles was 9.2. 33 pts had at least one 1 post-treatment tumor assessment. The confirmed ORR and DCR were 90.9% (30/33) and 100% (33/33) in all pts, were 89.5% (17/19) and 100% (19/19) in high-dose TRT group, and were 92.9% (13/14) and 100% (14/14) in low-dose TRT group. The median PFS was 10.2(CI: 5.8∼14.7) months in all pts, was 7 (CI: 3.8∼10.2) months in high-dose TRT group and 10.4 (CI: 8.4∼12.3) months in low-dose TRT group. AEs occurred in 27 (81.8%) pts and grade 3 or 4 AEs occurred in 20 (60.6%) pts. The most common grade 3 or 4 AEs included neutropenia (15, 45.5%), leukopenia (8, 24.2%), lymphocytopenia (5, 15.2%), pneumonia (3, 9.1%), anemia (3, 9.1%) and thrombocytopenia (2, 6.1%).

CONCLUSION

SHR-1316 plus chemotherapy and sequential TRT as first-line therapy for ES-SCLC showed promising efficacy and acceptable safety. There is no significant difference between high-dose and low-dose TRT groups in terms of safety and efficacy according to current data.

HPK1 Inhibition Enhancing HFRT Anti-Tumor Immune Response

PURPOSE/OBJECTIVE(S)

Radiation therapy, as one of the canonical treatments for classic tumors, results in impressive clinical responses. Stereotactic body radiotherapy (SBRT) has been increasingly used as one main therapy in early-stage non-small-cell lung cancer (NSCLC). SBRT affords good local tumor control, however, recurrence and metastasis are still the main causes of treatment failure. With the continuous deepening of the relationship between radiotherapy (RT) and immunity, reversing RT induced immunosuppression is considered to be a promising strategy to improve radiotherapy efficacy. Hematopoietic progenitor kinase 1 (HPK1) is mainly expressed in immune cells while rarely expressed in tumor cells. It has been proven to play a negative regulatory role in T cell receptor (TCR) signal. Therefore, we hypothesized that the combination of HPK1 inhibitor with SBRT would boost local and systemic anti-tumor immune responses by potentiating the anti-tumor effects of SBRT.

MATERIALS/METHODS

Using Digital Spatial Profiler (DSP), we analyzed HPK1 expression in the tumor specimens of 39 NSCLC patients treated with SBRT. By establishing mice subcutaneous tumor models, we assessed the combination of a HPK1 inhibitor and local hyper-fractionated radiotherapy (HFRT) on local and systemic tumor control and mouse survival. Using Single-cell RNA sequencing, Flow cytometry and pharmacological treatment, we analyzed and verified Tumor-infiltrating lymphocytes (TILs), and excavated the specific mechanism of the HPK1 inhibitor enhancing HFRT -induced anti -tumor immune response.

RESULTS

In the tumor specimens of NSCLC patients treated with SBRT, we found that high expression HPK1 in TILs predicted poor progression-free survival (PFS). Among the C57BL/6 mice model, HFRT combined with a HPK1 inhibitor promoted local response, and improved the survival rate of mice, showing better anti-tumor curative effects. We further showed that HFRT promoted CD8+ T cell cytotoxic activity, and also aggravated CD8+ T cell exhaustion. After the intervention of HPK1 small molecular inhibitors, the proportion of exhaustion CD8+T cells was significantly reduced, while CD8+T cell cytotoxic activity was further enhanced in the later period. Single-cell RNA sequencing and pharmacological inhibition of HPK1 revealed that HPK1 mediated the exhaustion of CD8+T cells by regulating RGS16. In abscopal effects preclinical models, BGB-15025 induced obvious abscopal effect.

CONCLUSION

Thus, we demonstrate that HPK1 mediates HFRT-induced CD8+T cell exhaustion by regulating RGS16, and HPK1 is an attractive drug target for enhancing local and systemic radiotherapy.

Using MRI Radiomics to Predict the Efficacy of Immunotherapy for Brain Metastasis in Patients with Non-small Cell Lung Cancer

PURPOSE/OBJECTIVE(S)

Despite immune checkpoint inhibitors (ICIs) has been proven effective in patients with advanced NSCLC, controversial therapeutic responses are seen in brain metastatic lesions. There are no robust biomarkers that predict benefit from this regimen. We evaluated the utility of novel imaging biomarkers (radiomics) to distinguish NSCLC patients with brain metastases (BMs) who will benefit from ICIs from those likely to progress despite therapy.

MATERIALS/METHODS

One-hundred and seventy-four NSCLC Patients with BMs treated with ICIs from June 2019 - June 2022 were identified. We collected patient clinical outcomes and pre-treatment MRI images. Images were split into training and test sets. Brain metastatic lesions were contoured on ITK-SNAP software and 3748 radiomic features capturing both intra- and peritumoral texture patterns were extracted. The primary endpoint of this study was intracranial progression-free survival (iPFS) and the secondary objective were progression-free survival (PFS) and overall survival (OS). We used the least absolute shrinkage and selection operator (LASSO) Cox regression model to build the radiomic signature for ORR. Based on the support vector machine (SVM) model, we construct the Clinical-radiomics nomogram (CRN). Multivariable Cox regression analysis were performed to evaluate the effect of each factor on iPFS. We performed Kaplan-Meier survival analysis and log-rank tests to assess prognostic value of the features.

RESULTS

We identified 174 patients who fit our criteria with available MRI images. 122 patients treated in our center were divided into a training set and 52 patients treated in another center were divided into a test set. The intratumoral radiomic signatures(IRS), peritumoral radiomic signatures(PRS) and CRN showed favorable predictive effects for ORR with the area under the receiver operating curve (AUC) of (IRS: 0.845 (95% CI: 0.776-0.914); PRS: 0.799 (95% CI:0.720-0.879); CRN:0.907 (95% CI: 0.855-0.959))in the training set and (IRS: 0.809 (95% CI: 0.693-0.926); PRS: 0.749 (95% CI:0.616-0.883); CRN:0.888(95% CI:0.798-0.979)) in the test set. Kaplan-Meier analyses showed a significantly longer iPFS in the high-CRN group versus the low-CRN group (P < 0.001). The CRNs were also found significantly associated with PFS (P < 0.001), but not OS.

CONCLUSION

Radiomic biomarkers from pre-treatment MRI images in NSCLC patients with BMs were predictive of iPFS to ICIs. Pre-treatment radiomics may allow early prediction of benefit and expedite more aggressive treatment for high-risk patients. Additional validation of these imaging biomarkers is warranted.

IKBKE Promotes Radioresistance of Glioblastoma through AKT/FOXO3a Pathway

PURPOSE/OBJECTIVE(S)

Glioblastoma is an intracranial highly malignant primary tumor, and postoperative radiotherapy is a common treatment of glioblastoma. While radiotherapy resistance of glioblastoma is an important reason for treatment failure. IKBKE is overexpressed in gliomas, but its role in radiotherapy is unknown. This study confirmed that IKBKE can directly phosphorylate AKT protein to regulate FOXO3a, thus promoting the radioresistance of glioblastoma, and proposed a new therapeutic strategy to enhance the efficacy of radiotherapy.

MATERIALS/METHODS

We used flow cytometry, tunel staining, plate cloning, a cell counting kit and WB to confirm the effects of IKBKE and FOXO3a on radioresistance of glioblastoma, and immunofluorescence and WB were used to detect the expression of γ-H2AX. Subcutaneous tumor formation in mice and immunohistochemical staining was performed. IP combined with mass spectrometry, immunofluorescence, endogenous and exogenous IP were used to confirm the interaction between IKBKE and AKT. Point mutation, IP and WB were used to confirm the phosphorylation site of AKT. IP and some small molecule inhibitors were used to confirm the relationship between IKBKE, AKT and PI3K. The effect of IKBKE on FOXO3a was confirmed by WB and qPCR. The protein relationship among IKBKE, FOXO3a and 14-3-3 was confirmed by CHX, MG132, ubiquitin test, immunofluorescence and IP. The above experiments were carried out to verify the effect of Amlexanox, an IKBKE inhibitor, on glioblastoma. And its pharmacokinetics in the brain was determined by LC-MS to provide a theoretical basis for further clinical use.

RESULTS

It was found that IKBKE could increase the radioresistance of glioblastoma in vitro and in vivo. IKBKE could directly phosphorylate AKT, and its phosphorylation sites were Ser473 and Thr308. We also certified that IKBKE activated AKT independent of PI3K. IKBKE inhibited the expression of FOXO3a on protein level, promoted its ubiquitin degradation, enhanced its interaction with 14-3-3, and inhibited its transportation into the nucleus. FOXO3a can increase the radiosensitivity of glioblastoma. Amlexanox, an IKBKE inhibitor, can inhibit the radiosensitivity of glioblastoma and partially pass through the blood-brain barrier to enhance the radiosensitivity of intracranial tumors.

CONCLUSION

IKBKE can activate AKT independent of PI3K by directly phosphorylating AKT Ser473 and Thr308, thus increasing the phosphorylation of FOXO3a. Phosphorylated FOXO3a promoted its ubiquitin degradation, and inhibited its transportation into the nucleus, causing radioresistance in glioblastoma. IKBKE inhibitor Amlexanox can pass through the blood-brain barrier and increase the radiosensitivity of intracranial tumor cells.

Effects of the PARP Inhibitor Niraparib on the Radiosensitivity of Human Lung and Cervical Cancer Cells

PURPOSE/OBJECTIVE(S)

DNA damage repair (DDR) initiated after DNA damage may lead to a decreased radiosensitivity of tumor cells or even radiation resistance. Previous studies indicate that PARP inhibitors block the repair of DNA single-strand breaks (SSBs), and unrepaired SSBs may continuously accumulate and form double-strand breaks (DSBs) that promotes tumor cell death. Studies have also shown that PARP inhibitors act synergistically with RT to inhibit DDR. In this study, we aim to investigate the effect of Niraparib, a clinically approved PARP inhibitor on the radiosensitivity of human lung and cervical cancer cells, and preliminarily explore the underlying mechanism.

MATERIALS/METHODS

The human lung cancer cell line A549 and human cervical cancer cell line Siha were both treated with niraparib (for 1h), or X-ray (4Gy), or Niraparib (for 1h) combined with X-ray (4Gy). The effect was examined via measurements of cell proliferation by the cell counting kit-8 assay, and cell viability was detected by clone formation assays. Cell apoptosis and cell cycle distribution were investigated by flow cytometry.

RESULTS

In human lung and cervical cancer cell lines, Niraparib combined with radiation therapy significantly inhibited cell proliferation. The proportion of apoptotic cells in cell lines treated with Niraparib plus radiation (the combination group) was significantly higher compared with control, radiation-only, and Niraparib-only groups. Additionally, the proportion of A549 cells in the G2/M phase was significantly increased in the combination group compared with the radiation-only group.

CONCLUSION

The results support that PARP inhibitor Niraparib increases the radiosensitivity of tumor cells, promotes their apoptosis, and induces cell cycle redistribution. The possible mechanism is associated with the inhibition of radiation-induced DNA damage repair.

Financial Toxicity and Out-of-Pocket Costs for Patients with Head and Neck Cancer: An Australian Perspective

PURPOSE/OBJECTIVE(S)

Financial toxicity is under-investigated for patients with head and neck cancer (HNC). The aim of this study was to quantify and describe the financial toxicity and out-of-pocket costs for patients with HNC in regional Australia and to consider its relationship with quality of life.

MATERIALS/METHODS

A cross-sectional survey was administered to patients with mucosal HNC who were disease free and 1-3 years after completion of radiotherapy at a regional tertiary hospital in Australia. The survey included questions on socio-demographics, out-of-pocket expenses, and health-related quality of life (HRQoL) measured with the FACT-H&N. Financial toxicity was evaluated using the Financial Index of Toxicity (FIT) survey, which scores financial toxicity on a scale of 0-100 (higher score indicating higher financial toxicity). The relationship between high financial toxicity scores (top quartile) and HRQoL was explored.

RESULTS

Of 57 total patients, 41 (72%) reported out-of-pocket expenses at a median of AU$1,796 (interquartile range AU$2,700) and a maximum of AU$25,050. The overall median FIT score was 13.9 (interquartile range 19.5) and patients with high financial toxicity (n = 14) reported poorer HRQoL (76.5 vs 114.5, p < 0.001). Patients who were not married had a higher financial toxicity score (23.1 vs 11.1, p = 0.01). Similarly, those participants with lower levels of education had higher financial toxicity (19.3 vs 11.1, p = 0.06). Participants with private health insurance were found to have lower rates of financial toxicity (8.3 vs 17.6, p = 0.01). Medications (41%, median AU$400), dietary supplements (41%, median AU$600), travel (36%, median AU$525) and dental (29%, AU$388) were the most common out-of-pocket expenses. Only nineteen patients (33%) reported that a member of their treating team had asked if they have any financial concerns. Participants living in rural locations (> 100km from the hospital) had higher out-of-pocket expenses (AU$2655 vs AU$730, p = 0.01).

CONCLUSION

Financial toxicity is a significant issue for a significant proportion of patients with head and neck cancer which was associated with a reduced HRQoL. All clinicians should consider asking patients with HNC about financial concerns and be aware of what financial support is available in their region. Interventions are required to reduce the burden of financial toxicity for patients with HNC.

Using MRI Radiomics to Predict the Efficacy of Immunotherapy for Brain Metastasis in Patients with Small Cell Lung Cancer

PURPOSE/OBJECTIVE(S)

Immune-checkpoint inhibitors (ICIs) combined with chemotherapy has been widely used in the first-line treatment of small cell lung cancer (SCLC) patients. However, the efficacy of ICIs for patients with brain metastases (BMs) of SCLC is limited. There are no effective factors to predict the efficacy. We developed and validate a model to predict intracranial efficacy for ICIs in patients with BMs from SCLC by using MRI radiomics.

MATERIALS/METHODS

In this study, we collected 101 SCLC patients with BMs treated with ICIs. They clinical characteristics and pre-treatment Magnetic Resonance Imaging (MRI) were collected. Seventy cases collected from our hospital as training cohort and 31 cases collected from another hospital as an independent validation cohort. Brain metastatic lesions were contoured on ITK-SNAP software and 3748 radiomic features capturing both intra- and peritumoral texture patterns were extracted. The primary endpoint of this study was intracranial overall response rate (ORR). Intraclass correlation coefficient (ICC) and random forest (RF) model were used to select radiomic features. The top 10 selected radiomic features were adopted to build prognostic models by using logistic regression. Area Under the Curve (AUC) of the Receiver Operating Characteristic (ROC) was chosen as the metric to assess model performances. We also performed a nomogram based on a multivariate logistic regression model includes radiomic and clinical features to predict ICIs intracranial efficacy.

RESULTS

The clinical characteristics including number of treatment lines and concurrent brain radiotherapy, ten intratumoral signatures and one peritumoral signatures were found significantly associated with ICIs intracranial efficacy. Predictors contained in the individualized prediction nomogram included the radiomics signature, and clinical features. The model showed favorable discrimination with a C-index of 0.861[95% CI: 0.779-0.943] and AUC of 0.861[95% CI: 0.778- 0.944] in training cohort and with a C-index of 0.812[95% CI: 0.647-0.978] and AUC of 0.812[95% CI:0.646-0.979] in the test cohort.

CONCLUSION

Radiomic features from pre-treatment MRI images were predictive for intracranial efficacy in SCLC patients with BMs. Pre-treatment radiomics may allow early prediction of benefit and expedite more aggressive treatment for high-risk patients and it has to be further explored as predictor of outcome in a larger series of patients.

The Baseline Serum Lipid Levels and Outcomes of NSCLC Patients Receiving Immunotherapy Combined or Non-Combined with Radiotherapy: A Single Center Retrospective Study

PURPOSE/OBJECTIVE(S)

In recent years, many studies have shown that lipids and lipid-like substances are key regulatory factors in tumor development and play an important role in immune regulation. However, it remains unclear whether serum lipids influence the outcome of immunotherapy. Therefore, determining the serum lipid levels of the immune treatment-beneficiary population may be valuable. The aim of this study is to evaluate the prognostic value of baseline serum lipid levels in non-small cell lung cancer (NSCLC) patients receiving immunotherapy.

MATERIALS/METHODS

We retrospectively included 294 patients with stage III-IV NSCLC who received immunotherapy continuously from December 2018 to November 2021 at our hospital, collecting their pre-treatment lipid levels, such as total cholesterol (TC), triglyceride (TG), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C). Of these, 160 receiving immunotherapy without combined radiotherapy (ICIs-nRT) and 134 combined with radiotherapy (iRT). The endpoint was the correlation between pre-treatment serum lipid levels and overall survival (OS), as well as progression-free survival (PFS). The X-tile tool was used to determine the optimal cut-off value of the indicators. The Kaplan-Meier survival curves were used to calculate OS and PFS and log rank tests were used for comparison. And the Cox proportional hazard model were used for univariate and multivariate analysis.

RESULTS

In all 294 patients, low TG, low TC, and low HDL-C predicted poor OS (P<0.001) and poor PFS (P<0.05). Low LDL-C was associated with poor OS (P = 0.0001). Among 160 patients receiving ICIs-nRT and 134 iRT patients, low levels of TG (P = 0.0134, 0.0024), TC (P = 0.0003, 0.0023), HDL-C (P = 0.0004, 0.0043), and LDL-C (P = 0.0003, 0.0419) were associated with worse OS compared to high levels of them. In the ICIs-nRT patients, low HDL-C predicted poor PFS (P = 0.0011). In 134 iRT patients, low levels of TG (P = 0.0017), TC (P = 0.0028), and LDL-C (P = 0.0330) were poor prognostic factors for PFS. In the univariate and multivariate analysis with OS in all patients, TG and HDL-C were independent risk factors, while TG was an independent risk factor in the analysis with PFS. In ICIs-nRT patients, HDL-C was an independent prognostic factor for patients' OS and PFS. In iRT patients, both TG and HDL-C were prognostic risk factors for OS.

CONCLUSION

These data confirm that higher serum lipid levels are associated with better outcomes in patients with NSCLC undergoing immunotherapy. Serum lipids may identify tumors that are more likely to respond to immunotherapy. Radiation therapy may affect lipid metabolism within the body to enhance the efficacy of immunotherapy.

Single-Cell Dissection of Concurrent Chemoradiotherapy-Induced Immunosenescence in Cervical Cancer

PURPOSE/OBJECTIVE(S)

Immunosenescence could attenuate effective anti-tumor immune response, but it's role in the tumor microenvironment following concurrent chemoradiotherapy (CCRT) in cervical cancer (CC) remains largely unknown. We aimed to investigate CCRT induced immunosenescence and its clinical implications in CC at single-cell resolution.

MATERIALS/METHODS

A total of 11326 cells from single-cell RNA sequencing data derived from five post-CCRT CC tumor samples were analyzed by bioinformatics for immunosenescence. Functional enrichment analysis including Gene Ontology (GO) and Gene Set Variation analysis was performed to identify and assess the molecular heterogeneity of cell subclusters. Kaplan-Meier survival analysis was performed in the bulk RNA-sequencing data included 253 patients with CC obtained from the The Cancer Genome Atlas.

RESULTS

We identified senescent and non-senescent cell clusters in tumor-associated macrophages (TAMs), CD8+ T cells and NK cells after CCRT based on the senescence-related genes expression. GO analysis showed that antigen processing and presentation pathways were enriched in the non-senescent TAMs, while the response to hypoxia and oxidative stress were enriched in the senescent TAMs, which repressed the anti-tumor immunity. We further found that the abundance of senescent TAMs was associated with shorter overall survival (OS) of patients with CC (P<0.001). Moreover, compared to senescent CD8+ T, non-senescent CD8+ T exhibited higher cytotoxicity and exhausted signature scores, and increased enrichment of T cell proliferation, differentiation and activation pathways. In addition, the high proportion of non-senescent NK cell was also associated with better OS of CC patients (P = 0.008).

CONCLUSION

We revealed the potential immune suppressive characteristics of CCRT induced senescent immune cells at single-cell resolution, which provides promising therapeutic targets for CC patients.

Enhancing Immune-Mediated Radiotherapy Efficacy in Murine Models of Head and Neck Cancer through Peroxisome Proliferator-Activated Receptor Modulation

PURPOSE/OBJECTIVE(S)

The tumor microenvironment (TME) in HPV-unrelated head and neck cancer (HNC) is considered to be immunologically "cold," and immunometabolic adaptations to radiotherapy (RT) can exacerbate these conditions and lead to radioresistance. Peroxisome proliferator-activated receptor-α (PPARα) agonism may improve the immune response to RT by reducing glucose scarcity through upregulation of fatty acid utilization in cancer cells. Our clinical trial data shows that high serum oleic acid (OA), a PPAR ligand, correlates with response to radioimmunotherapy.

MATERIALS/METHODS

Orthotopic buccal tumor implantations of MOC2 and LY2 HNC cell lines were performed in C57BL/6 and BALB/c mice, respectively. Mice were placed on a high OA diet (38% kcal from OA) 3 weeks prior to tumor implantation. Control diet consisted of 1% kcal from OA. In vitro RT was performed to characterize the metabolic effects on the cancer cell lines. For in vivo studies, tumors were irradiated upon reaching 100 mm^3 with three 8 Gy fractions, given every 4-5 days. The PPARα agonist fenofibrate (FF, 100mg/kg/day) was given via oral gavage or intraperitoneal injection starting 5 days after RT. Tumor volume and overall survival were measured as objective outcomes, and flow cytometry was used to characterize the immune landscape of the tumor, blood, and lymph nodes. Mass spectrometry was employed for bulk proteomics and metabolomics on serum samples, and stable isotope labeling was performed on CD8 T cells from treated mice ex vivo. Extracellular flux analyses were performed on tumor cells and CD8 T cells to determine metabolic phenotypic changes.

RESULTS

In vitro cytotoxicity was met for MOC2 and LY2 cancer cells in 100 uM FF and OA in comparison to solvent (p<0.01). Extracellular flux analyses show that RT upregulates the glycolytic phenotype of MOC2 and LY2 cancer cells; and that FF and/or OA decrease the glycolytic capacity of the cancer cells. Ex vivo extracellular flux analyses showed increased glycolytic capacity of CD8 T cells in mice treated with FF in comparison to RT alone. RT in combination with FF significantly improved tumor volume response in comparison to RT alone (mean 99.4 vs 182.7 mm^3, p = 0.001) and was comparable to combination radioimmunotherapy (with anti-PDL1 therapy; mean 99.4 vs. 132.3 mm^3). Unexpectedly, OA negated this improvement in efficacy in both MOC2 and LY2 tumor models; mice on the high OA diet had significantly higher average body weight (p<0.01). Significant changes in adaptive immune response were observed within the TME with the addition of FF. This was mirrored by changes in serum metabolomics.

CONCLUSION

PPARα agonism improved the efficacy of RT in murine HNC models and could be considered in future translational clinical trial design.